← 產業報告目錄

In Vitro Diagnostics Market by Product & Service (Kits, Instruments), Technology (Immunoassay, Hematology, Glucose Monitoring), Specimen (Blood), Site of Testing, Application (Endocrinology, Cardiology, Infectious Diseases) & Region- Global Forecast to 2030

出版商 MarketsandMarkets產業別 Medical Devices出版日期 2025-05-09頁數 740報告編號 MD3609

授權報價

Single User Licence$4,950 USD
Multi User Licence$6,650 USD
Corporate User Licence$8,150 USD
Global User Licence$10,000 USD
洽詢購買 申請 Sample

報告摘要

The global In vitro diagnostics market is projected to reach USD 157,632.5 million by 2030 from USD 109,065.5 million in 2025, at a CAGR of 7.6% during the forecast period. This is due to the increasing global burden of chronic diseases such as diabetes, cardiovascular conditions, cancer, and infectious diseases (e.g., HIV, tuberculosis). Demand for faster results, decentralized testing, and home-based diagnostics are pushing growth in point-of-care (POC) testing devices, innovations such as high-throughput systems, lab-on-a-chip, next-generation sequencing (NGS), and POC diagnostics, and government and private sector investments in healthcare infrastructure, especially in developing economies, are improving access to diagnostic services. The reagents & kits segment is expected to grow at the highest CAGR during the forecast period. Based on the product, the in vitro diagnostics market is divided into reagents & kits, instruments, and data management software & services. In 2024, the reagents & kits segment grew at the highest CAGR in vitro diagnostics market. This is due to the growing number of tests across hospitals, labs, and home settings, the expansion of rapid and self-testing kits, especially for glucose, pregnancy, and infectious disease detection, the expansion of clinical laboratories, diagnostic chains, and POC testing environments increases reagent usage. Continuous product launches and regulatory approvals—such as CE-IVD marking and FDA clearances—are expanding the portfolio and accessibility of specialized test kits across various clinical applications. The infectious diseases segment of the in vitro diagnostics market, by application, is expected to hold the largest market share during the forecast period. Based on application, the in vitro diagnostics market is segmented into infectious diseases, oncology, endocrinology, cardiology, blood screening, genetic testing, autoimmune diseases, allergy diagnostic, drug monitoring & testing, bone & mineral disorders, coagulation testing, blood group typing, and other applications. The infectious disease segment accounts for the largest market share of the in vitro diagnostics market due to the continued prevalence of diseases such as HIV, hepatitis, and tuberculosis, and emerging threats such as Malaria and Mpox, the need for fast, accessible testing—especially in remote or resource-limited settings—has boosted the adoption of portable and easy-to-use IVD kits for infectious diseases, and technologies such as RT-PCR (Reverse transcription polymerase chain reaction) and syndromic panel testing enable accurate, high-throughput diagnosis of multiple pathogens, driving growth in hospital and lab settings. Asia Pacific is expected to hold the highest CAGR in the in vitro diagnostics market during the forecast period. The global in vitro diagnostics market is segmented into six major regions, namely, North America, Europe, Asia Pacific, Latin America, Middle East & Africa, and GCC Countries. Asia Pacific is estimated to grow at the highest CAGR during the forecast period. The IVD market in the Asia Pacific region is growing rapidly due to the increasing prevalence of communicable and non-communicable diseases, especially in highly populated countries such as China and India. These countries are seeing a rise in conditions such as diabetes, cancer, cardiovascular diseases, tuberculosis, and hepatitis. Concurrently, the aging population is driving the IVD market in the Asia Pacific region, especially in Japan, South Korea, and China. For instance, within China, 216.76 million people are aged 65 and above, or 15.4% of the population, a 2023 report by China's Ministry of Civil Affairs and the China National Committee on Aging stated. This trend is resulting in a growing demand for chronic disease monitoring and regular diagnostics. In an effort to increase local production and decrease the reliance on imports, regional governments are promoting the manufacture of diagnostic reagents, kits, and equipment locally, thus also fuelling the growth of the market. A breakdown of the primary participants referred to for this report is provided below: • By Company Type: Tier 1- 42%, Tier 2- 30%, and Tier 3- 28% • By Designation: C-level- 46%, Director level- 23%, and Others- 31% • By Region: North America- 23%, Europe- 45%, Asia Pacific- 28%, Latin America- 3%, Middle East & Africa- 0.5%, and GCC Countries- 0.5 % Note 1: Companies are classified into tiers based on their total revenue. As of 2023, Tier 1 = >USD 10.0 billion, Tier 2 = USD 1.0 billion to USD 10.0 billion, and Tier 3 = <USD 1.0 billion. Note 2: C-level primaries include CEOs, CFOs, COOs, and VPs. Note 3: Others include sales managers, marketing managers, business development managers, product managers, distributors, and suppliers. The major players operating in the in vitro diagnostics market include Danaher (US), F. Hoffmann-La Roche Ltd (Switzerland), Abbott (US), Siemens Healthineers AG (Germany), Thermo Fisher Scientific Inc. (US), Illumina, Inc. (US), Hologic, Inc. (US), Bio-Rad Laboratories, Inc. (US), bioMérieux (France), Sysmex Corporation (Japan), Revvity (US), Becton, Dickinson and Company (US), Agilent Technologies, Inc. (US), Qiagen (Germany), DiaSorin S.p.A. (Italy), Grifols, S.A. (Spain), Werfen (Spain), and QuidelOrtho Corporation, (US) among others. Research Coverage This report studies the in vitro diagnostics market based on product & service, technology, specimen, site of testing, application, end user, and region. The report also studies factors (such as drivers, restraints, opportunities, and challenges) affecting market growth and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micro markets with respect to their individual growth trends and forecasts the revenue of the market segments with respect to six major regions (and the respective countries in these regions). Reasons to Buy the Report The report will enable established firms as well as entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them to gain a larger market share. Firms purchasing the report could use one or a combination of the below-mentioned strategies to strengthen their market presence. This report provides insights on the following points: • Analysis of key drivers (Increasing geriatric population and subsequent rise in chronic diseases, growing awareness of early disease diagnosis in emerging economies, emergence of rapid PoC technologies and rising adoption of automated analyzers, growing preference for personalized medicines), restraints (Unfavorable reimbursement scenario, stringent regulatory requirements, High cost of diagnostic equipment), opportunities (introduction of disease-specific biomarkers and tests, increasing significance of companion diagnostics, growth opportunities in developing countries, Improvements in immunoassay diagnostic technologies, digitalization trend), challenges (operational barriers, data privacy, and cybersecurity risks) • Market Penetration: Complete knowledge of the spectrum of products presented by the major companies in the in vitro diagnostics market • Product Development/Innovation: Comprehensive understanding of the forthcoming trends, research and development initiatives, and product launches within the in vitro diagnostics market • Market Development: Complete knowledge about profitable developing regions • Market Diversification: Exhaustive knowledge of new goods, expanding geographies, and current changes in the in vitro diagnostics industry helps to diversify the market • Competitive Assessment: Comprehensive evaluation of market segmentation, development plans, income analysis, and goods of the top market participants
目錄 Table of Contents
1 INTRODUCTION 57 1.1 STUDY OBJECTIVES 57 1.2 MARKET DEFINITION 57 1.3 STUDY SCOPE 58 1.3.1 MARKETS COVERED AND REGIONAL SCOPE 58 1.3.2 INCLUSIONS AND EXCLUSIONS 59 1.3.3 YEARS CONSIDERED 60 1.4 CURRENCY CONSIDERED 60 1.5 STAKEHOLDERS 61 1.6 SUMMARY OF CHANGES 61 2 RESEARCH METHODOLOGY 62 2.1 RESEARCH DATA 62 2.1.1 SECONDARY RESEARCH 63 2.1.1.1 Key data from secondary sources 64 2.1.2 PRIMARY DATA 65 2.1.2.1 Primary sources 65 2.1.2.2 Key data from primary sources 66 2.1.2.3 Key industry insights 67 2.2 MARKET SIZE ESTIMATION 68 2.2.1 BOTTOM-UP APPROACH 69 2.2.1.1 Approach 1: Company revenue estimation approach 69 2.2.1.2 Approach 2: Presentations of companies and primary interviews 70 2.2.1.3 Growth forecast 70 2.2.2 TOP-DOWN APPROACH 71 2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 72 2.4 MARKET SHARE ANALYSIS 73 2.5 RESEARCH ASSUMPTIONS 73 2.5.1 PARAMETRIC ASSUMPTIONS 73 2.5.2 GROWTH RATE ASSUMPTIONS 74 2.6 RESEARCH LIMITATIONS 74 2.7 RISK ASSESSMENT 74 3 EXECUTIVE SUMMARY 75   4 PREMIUM INSIGHTS 82 4.1 IN VITRO DIAGNOSTICS MARKET OVERVIEW 82 4.2 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE AND COUNTRY, 2024 83 4.3 IN VITRO DIAGNOSTICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 84 4.4 IN VITRO DIAGNOSTICS MARKET: GEOGRAPHIC MIX 84 4.5 IN VITRO DIAGNOSTICS MARKET: EMERGING ECONOMIES VS. DEVELOPED MARKETS 85 5 MARKET OVERVIEW 86 5.1 INTRODUCTION 86 5.2 MARKET DYNAMICS 86 5.2.1 DRIVERS 87 5.2.1.1 Increasing geriatric population and subsequent rise in chronic diseases 87 5.2.1.2 Growing awareness of early disease diagnosis in emerging economies 88 5.2.1.3 Emergence of rapid PoC technologies and rising adoption of automated analyzers 89 5.2.1.4 Growing preference for personalized medicines 89 5.2.2 RESTRAINTS 90 5.2.2.1 Unfavorable reimbursement scenario 90 5.2.2.2 Stringent regulatory requirements 90 5.2.2.3 High cost of diagnostic equipment 92 5.2.3 OPPORTUNITIES 92 5.2.3.1 Introduction of disease-specific biomarkers and tests 92 5.2.3.2 Increasing significance of companion diagnostics 93 5.2.3.3 Growth opportunities in developing countries 94 5.2.3.4 Improvements in immunoassay diagnostic technologies 95 5.2.3.5 Digitalization trend 96 5.2.4 CHALLENGES 96 5.2.4.1 Operational barriers 96 5.2.4.2 Data privacy and cybersecurity risks 97 5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS 98 5.4 PRICING ANALYSIS 98 5.4.1 AVERAGE SELLING PRICE TREND, BY KEY PLAYER 98 5.4.2 AVERAGE SELLING PRICE TREND, BY REGION 100 5.4.3 AVERAGE SELLING PRICE TREND, BY PRODUCT 100 5.5 VALUE CHAIN ANALYSIS 102 5.5.1 RESEARCH & DEVELOPMENT 102 5.5.2 RAW MATERIAL SUPPLIERS 102 5.5.3 MANUFACTURING 102 5.5.4 DISTRIBUTION, MARKETING, AND SALES 102 5.5.5 RETAILERS 102 5.5.6 POST-SALES SERVICES 102 5.6 SUPPLY CHAIN ANALYSIS 103 5.6.1 PROMINENT COMPANIES 103 5.6.2 SMALL & MEDIUM-SIZED ENTERPRISES 104 5.6.3 END USERS 104 5.7 ECOSYSTEM ANALYSIS 104 5.8 INVESTMENT AND FUNDING SCENARIO 106 5.9 TECHNOLOGY ANALYSIS 107 5.9.1 KEY TECHNOLOGIES 107 5.9.2 COMPLEMENTARY TECHNOLOGIES 108 5.9.2.1 Immunohistochemistry 108 5.10 PATENT ANALYSIS 109 5.11 TRADE ANALYSIS 111 5.11.1 IMPORT DATA FOR HS CODE 382200 111 5.11.2 EXPORT DATA FOR HS CODE 382200 112 5.12 KEY CONFERENCES AND EVENTS, 2025–2026 112 5.13 CASE STUDY ANALYSIS 113 5.13.1 CASE STUDY 1: LOCALIZED STRATEGY TO TAP MARKET POTENTIAL IN EUROPE 113 5.13.2 CASE STUDY 2: ENHANCED COMPANY FOOTPRINT IN COMPETITIVE INDIAN MARKET 114 5.13.3 CASE STUDY 3: CUSTOMER-CENTRIC DIFFERENTIATION FOR PRODUCT OPTIMIZATION AND PREMIUM PRICING 115 5.14 REGULATORY LANDSCAPE 115 5.14.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 116 5.15 REGULATORY FRAMEWORK 118 5.15.1 NORTH AMERICA 118 5.15.1.1 US 118 5.15.1.2 Canada 120 5.15.2 EUROPE 120 5.15.3 ASIA PACIFIC 122 5.15.3.1 Japan 122 5.15.3.2 China 123 5.15.3.3 India 124 5.15.3.4 South Korea 124 5.15.3.5 Indonesia 125 5.15.3.6 Russia 126 5.15.4 MIDDLE EAST & AFRICA 126 5.15.4.1 Saudi Arabia 126 5.15.4.2 Africa 127 5.15.5 LATIN AMERICA 127 5.15.5.1 Mexico 127 5.15.5.2 Brazil 128 5.16 PORTER’S FIVE FORCES ANALYSIS 128 5.16.1 BARGAINING POWER OF SUPPLIERS 130 5.16.2 BARGAINING POWER OF BUYERS 130 5.16.3 THREAT OF NEW ENTRANTS 130 5.16.4 THREAT OF SUBSTITUTES 130 5.16.5 INTENSITY OF COMPETITIVE RIVALRY 130 5.17 KEY STAKEHOLDERS AND BUYING CRITERIA 131 5.17.1 KEY STAKEHOLDERS IN BUYING PROCESS 131 5.17.2 BUYING CRITERIA 132 5.18 RECENT POLICY CHANGES IN US MARKET AND THEIR POTENTIAL IMPACT ON APPROVAL PROCESS 133 5.19 INFLUENCE OF TARIFFS ON SUPPLY CHAIN RESILIENCE OF MEDTECH COMPANIES 135 5.20 GROWTH OF DECENTRALIZED TESTING VS. ADOPTION OF COST-EFFECTIVE CENTRALIZED TESTING 136 5.21 IMPACT OF AI/GENERATIVE AI ON IN VITRO DIAGNOSTICS MARKET 138 5.21.1 INTRODUCTION 138 5.21.2 MARKET POTENTIAL OF AI IN IVD DEVICES 138 5.21.3 AI USE CASES 139 5.21.4 KEY COMPANIES IMPLEMENTING AI 140 5.21.5 FUTURE OF GENERATIVE AI IN IN VITRO DIAGNOSTICS MARKET 140 6 IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE 141 6.1 INTRODUCTION 142 6.2 REAGENTS & KITS 142 6.2.1 RISE IN TEST VOLUMES ACROSS CLINICAL LABS, HOSPITALS, AND POINT-OF-CARE SETTINGS TO AID GROWTH 142 6.3 INSTRUMENTS 146 6.3.1 GROWING TREND OF AUTOMATION TO DRIVE MARKET 146 6.4 DATA MANAGEMENT SOFTWARE & SERVICES 151 6.4.1 INCREASING SHIFT TOWARD CLOUD-BASED PLATFORMS AND REMOTE DATA ACCESS TO STIMULATE GROWTH 151 7 IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY 156 7.1 INTRODUCTION 157 7.2 IMMUNOASSAYS 157 7.2.1 ENZYME-LINKED IMMUNOSORBENT ASSAYS (ELISA) 162 7.2.1.1 Increasing use of immunoassays in cancer, infectious disease testing, and therapeutic drug monitoring to aid growth 162 7.2.2 CHEMILUMINESCENCE IMMUNOASSAYS 166 7.2.2.1 Need for minimal human intervention to support growth 166 7.2.3 IMMUNOFLUORESCENCE ASSAYS 171 7.2.3.1 Growing introduction of innovative diagnostic platforms to drive market 171 7.2.4 RAPID TESTS 174 7.2.4.1 Need for rapid diagnostic tests to expedite growth 174 7.2.5 ENZYME-LINKED IMMUNOSPOT ASSAYS (ELISPOT) 178 7.2.5.1 Need for early detection and monitoring of immune-related disorders to amplify growth 178 7.2.6 WESTERN BLOTTING 182 7.2.6.1 Increasing focus on biomarker discovery and personalized treatment to advance growth 182 7.2.7 OTHER IMMUNOASSAY TECHNOLOGIES 185 7.3 CLINICAL CHEMISTRY 188 7.3.1 BASIC METABOLIC PANELS 194 7.3.1.1 Increasing incidence of diabetes, kidney disorders, and hypertension to promote growth 194 7.3.2 LIVER PANELS 197 7.3.2.1 Rising prevalence of cirrhosis and viral hepatitis to foster growth 197 7.3.3 RENAL PROFILES 201 7.3.3.1 Growing awareness for preventive health check-ups to boost market 201 7.3.4 LIPID PROFILES 204 7.3.4.1 Rising prevalence of obesity to accelerate growth 204 7.3.5 THYROID FUNCTION PROFILES 208 7.3.5.1 High incidence of thyroid-related disorders to support growth 208 7.3.6 ELECTROLYTE PANELS 211 7.3.6.1 Growing shift toward home care and remote patient monitoring to fuel market 211 7.3.7 SPECIALTY CHEMICAL TESTS 215 7.3.7.1 Rising demand for specialized tests to contribute to growth 215 7.4 MOLECULAR DIAGNOSTICS 218 7.4.1 POLYMERASE CHAIN REACTION 223 7.4.1.1 High accuracy and speed in detecting pathogens to aid growth 223 7.4.2 ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY 227 7.4.2.1 Growing focus on rapid, onsite molecular diagnostics to propel market 227 7.4.3 DNA SEQUENCING & NEXT-GENERATION SEQUENCING 231 7.4.3.1 Growing applications in research, drug discovery, and molecular diagnostics to boost market 231 7.4.4 IN SITU HYBRIDIZATION 235 7.4.4.1 Rising prevalence of cancer and genetic disorders to assist growth 235 7.4.5 DNA MICROARRAYS 238 7.4.5.1 High resolution and throughput capabilities to favor growth 238 7.4.6 OTHER MOLECULAR DIAGNOSTIC TECHNOLOGIES 241 7.5 GLUCOSE MONITORING 244 7.5.1 ONGOING TECHNOLOGICAL ADVANCEMENTS IN BLOOD GLUCOSE SELF-MONITORING DEVICES TO AID GROWTH 244 7.6 HEMATOLOGY 248 7.6.1 GROWING FOCUS ON STEM CELL RESEARCH TO BOOST MARKET 248 7.7 MICROBIOLOGY 251 7.7.1 RISING PREVALENCE OF MICROBIAL INFECTIONS TO SUSTAIN GROWTH 251 7.8 COAGULATION & HEMOSTASIS 254 7.8.1 GROWING CASES OF PULMONARY EMBOLISM, HEMOPHILIA, LIVER DISEASES TO DRIVE MARKET 254 7.9 BLOOD GAS ANALYZERS 258 7.9.1 GROWING SURGICAL INTERVENTIONS AND RISE IN ELDERLY POPULATION TO FUEL MARKET 258 7.10 URINALYSIS 262 7.10.1 RISING INCIDENCE OF URINARY TRACT INFECTIONS TO SUPPORT GROWTH 262 7.11 CHROMATOGRAPHY & MASS SPECTROMETRY 265 7.11.1 INCREASING APPLICATIONS IN DISEASE SCREENING AND DIAGNOSTICS TO AID GROWTH 265 8 IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN 270 8.1 INTRODUCTION 271 8.2 BLOOD, SERUM, AND PLASMA SPECIMENS 271 8.2.1 GROWING SHIFT TOWARD DECENTRALIZED TESTING TO PROPEL MARKET 271 8.3 SALIVA SPECIMENS 275 8.3.1 GROWING ADVANCEMENTS IN MOLECULAR DIAGNOSTICS TO BOOST MARKET 275 8.4 URINE SPECIMENS 278 8.4.1 RISING INCIDENCE OF URINARY TRACT INFECTIONS TO ACCELERATE GROWTH 278 8.5 OTHER SPECIMENS 282 9 IN VITRO DIAGNOSTICS MARKET, BY SITE OF TESTING 286 9.1 INTRODUCTION 287 9.2 LABORATORY TESTS 287 9.2.1 INCREASING FOCUS ON EARLY AND ACCURATE DISEASE DETECTION TO ENCOURAGE GROWTH 287 9.3 POINT-OF-CARE TESTS 293 9.3.1 RISING DEMAND FOR DECENTRALIZED HEALTHCARE TO CONTRIBUTE TO GROWTH 293 10 IN VITRO DIAGNOSTICS MARKET, BY APPLICATION 299 10.1 INTRODUCTION 300 10.2 INFECTIOUS DISEASES 301 10.2.1 INCREASING PREVALENCE OF VIRAL, BACTERIAL, AND PARASITIC INFECTIONS TO PROMOTE GROWTH 301 10.3 ONCOLOGY 304 10.3.1 RISING GLOBAL BURDEN OF CANCER TO EXPEDITE GROWTH 304 10.4 ENDOCRINOLOGY 308 10.4.1 INCREASING PREVALENCE OF DIABETES AND THYROID-RELATED DISORDERS TO BOLSTER GROWTH 308 10.5 CARDIOLOGY 312 10.5.1 GROWING USE OF IMMUNOASSAYS IN CARDIOVASCULAR DISEASE DETECTION TO DRIVE MARKET 312 10.6 BLOOD SCREENING 315 10.6.1 RISING INCIDENCE OF HIV AND SYPHILIS TO SUPPORT GROWTH 315 10.7 GENETIC TESTING 319 10.7.1 INCREASING CLINICAL UTILITY OF GENETIC TESTS ACROSS ONCOLOGY, RARE DISEASES, AND REPRODUCTIVE HEALTH TO FOSTER GROWTH 319 10.8 AUTOIMMUNE DISEASES 322 10.8.1 RISE IN AUTOIMMUNE CONDITIONS GLOBALLY TO FACILITATE GROWTH 322 10.9 ALLERGY DIAGNOSTICS 326 10.9.1 INCREASING AWARENESS ABOUT ALLERGIES TO AMPLIFY GROWTH 326 10.10 DRUG MONITORING & TESTING 330 10.10.1 INCREASING ILLICIT DRUG CONSUMPTION TO SUSTAIN GROWTH 330 10.11 BONE & MINERAL DISORDERS 334 10.11.1 RISING CASES OF OSTEOPOROSIS TO FUEL MARKET 334 10.12 COAGULATION TESTING 338 10.12.1 INCREASING PREVALENCE OF HEMOPHILIA TO ADVANCE GROWTH 338 10.13 BLOOD GROUP TYPING 341 10.13.1 RISING NUMBER OF SURGICAL PROCEDURES TO SPEED UP GROWTH 341 10.14 OTHER APPLICATIONS 345 11 IN VITRO DIAGNOSTICS MARKET, BY END USER 349 11.1 INTRODUCTION 350 11.2 HOSPITALS & CLINICS 350 11.2.1 EXPANDING HEALTHCARE INFRASTRUCTURE TO SPEED UP GROWTH 350 11.3 CLINICAL LABORATORIES 354 11.3.1 LARGE REFERENCE LABORATORIES 358 11.3.1.1 Growing test volume and complexity of diagnostic testing to propel market 358 11.3.2 SMALL AND MEDIUM-SIZED LABORATORIES 361 11.3.2.1 Increasing shift toward community-based and point-of-care settings to foster growth 361 11.4 BLOOD BANKS 364 11.4.1 NEED TO ADDRESS PUBLIC HEALTH AND SAFETY CHALLENGES TO AID GROWTH 364 11.5 HOME CARE SETTINGS 368 11.5.1 GROWING INCLINATION TOWARD SELF-DIAGNOSIS AND MONITORING TO BOOST MARKET 368 11.6 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 372 11.6.1 INCREASING USE OF IVD PRODUCTS IN CLINICAL DRUG DEVELOPMENT AND COMPANION DIAGNOSTICS TO DRIVE MARKET 372   11.7 ACADEMIC INSTITUTES 375 11.7.1 RISING INDUSTRY-ACADEMIA COLLABORATIONS FOR PRODUCT DEVELOPMENT TO AUGMENT GROWTH 375 11.8 OTHER END USERS 378 12 IN VITRO DIAGNOSTICS MARKET, BY REGION 382 12.1 INTRODUCTION 383 12.2 NORTH AMERICA 383 12.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 384 12.2.2 US 392 12.2.2.1 Established reimbursement framework and favorable policies for IVD providers to drive market 392 12.2.3 CANADA 399 12.2.3.1 Favorable funding initiatives for early disease diagnosis to fuel market 399 12.3 EUROPE 405 12.3.1 MACROECONOMIC OUTLOOK FOR EUROPE 406 12.3.2 GERMANY 413 12.3.2.1 Increasing investments in clinical diagnostics research to aid growth 413 12.3.3 FRANCE 418 12.3.3.1 High healthcare expenditure and rising investments in genomic medicine to drive market 418 12.3.4 UK 424 12.3.4.1 Rising adoption of genome-based testing to encourage growth 424 12.3.5 ITALY 430 12.3.5.1 Growing geriatric population and subsequent rise in chronic conditions to boost market 430 12.3.6 SPAIN 436 12.3.6.1 Increasing adoption of technologically advanced immunoassay systems to expedite growth 436 12.3.7 RUSSIA 441 12.3.7.1 High incidence of respiratory infectious diseases to boost market 441 12.3.8 SWITZERLAND 447 12.3.8.1 Growing prevalence of chronic diseases to propel market 447 12.3.9 REST OF EUROPE 453 12.4 ASIA PACIFIC 459 12.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 460 12.4.2 JAPAN 468 12.4.2.1 Increasing research investments for immunoassays to encourage growth 468 12.4.3 CHINA 473 12.4.3.1 Growing focus on preventive care to boost market 473 12.4.4 INDIA 479 12.4.4.1 Rising incidence of diabetes and cancer to augment growth 479 12.4.5 SOUTH KOREA 485 12.4.5.1 Rising healthcare spending for innovative IVD technologies to amplify growth 485 12.4.6 AUSTRALIA 491 12.4.6.1 Increasing incidence of chronic diseases and rising blood donations to fuel market 491 12.4.7 SINGAPORE 497 12.4.7.1 Rising technological advancements and automation to stimulate growth 497 12.4.8 REST OF ASIA PACIFIC 502 12.5 LATIN AMERICA 508 12.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 508 12.5.2 BRAZIL 514 12.5.2.1 Rising prevalence of diabetes to sustain growth 514 12.5.3 MEXICO 520 12.5.3.1 Growing establishment of clinical laboratories to fuel market 520 12.5.4 REST OF LATIN AMERICA 526 12.6 MIDDLE EAST & AFRICA 533 12.6.1 GROWING FOCUS ON PRENATAL AND CANCER TESTING TO DRIVE MARKET 533 12.6.2 MIDDLE EAST & AFRICA: MACROECONOMIC OUTLOOK 533 12.7 GCC COUNTRIES 538 12.7.1 GCC COUNTRIES: MACROECONOMIC OUTLOOK 539 12.7.2 SAUDI ARABIA 544 12.7.2.1 Rising government healthcare expenditure to boost market 544 12.7.3 UAE 550 12.7.3.1 Improvements in healthcare infrastructure to support growth 550 12.7.4 OTHER GCC COUNTRIES 555 13 COMPETITIVE LANDSCAPE 561 13.1 OVERVIEW 561 13.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 561 13.3 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS 562 13.4 REVENUE ANALYSIS, 2022–2024 563 13.5 MARKET SHARE ANALYSIS, 2024 564 13.6 COMPANY VALUATION AND FINANCIAL METRICS 566 13.7 BRAND/PRODUCT COMPARISON 567 13.8 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024 568 13.8.1 STARS 568 13.8.2 EMERGING LEADERS 568 13.8.3 PERVASIVE PLAYERS 568 13.8.4 PARTICIPANTS 568 13.8.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024 570 13.8.5.1 Company footprint 570 13.8.5.2 Region footprint 571 13.8.5.3 Product & service footprint 572 13.8.5.4 Technology footprint 573 13.8.5.5 End-user footprint 574 13.9 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024 575 13.9.1 PROGRESSIVE COMPANIES 575 13.9.2 RESPONSIVE COMPANIES 575 13.9.3 DYNAMIC COMPANIES 575 13.9.4 STARTING BLOCKS 575 13.9.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024 577 13.9.5.1 Detailed list of key startups/SMEs 577 13.9.5.2 Competitive benchmarking of key startups/SMEs 578 13.10 COMPETITIVE SCENARIO 579 13.10.1 PRODUCT LAUNCHES AND APPROVALS 579 13.10.2 DEALS 580 13.10.3 EXPANSIONS 581 13.11 POTENTIAL FUTURISTIC STRATEGIES OF LEADING PLAYERS OPERATING IN IVD MARKET 582 13.11.1 PRODUCT LAUNCHES AND APPROVALS 583 13.11.2 DEALS 583 14 COMPANY PROFILES 585 14.1 KEY PLAYERS 585 14.1.1 DANAHER 585 14.1.1.1 Business overview 585 14.1.1.2 Products/Services offered 587 14.1.1.3 Recent developments 590 14.1.1.3.1 Product launches and approvals 590 14.1.1.3.2 Deals 591 14.1.1.3.3 Expansions 592 14.1.1.4 MnM view 593 14.1.1.4.1 Key strengths 593 14.1.1.4.2 Strategic choices 593 14.1.1.4.3 Weaknesses and competitive threats 593 14.1.2 F. HOFFMANN-LA ROCHE LTD 594 14.1.2.1 Business overview 594 14.1.2.2 Products/Services offered 596 14.1.2.3 Recent developments 599 14.1.2.3.1 Product launches and approvals 599 14.1.2.3.2 Deals 601 14.1.2.3.3 Expansions 602 14.1.2.4 MnM view 602 14.1.2.4.1 Key strengths 602 14.1.2.4.2 Strategic choices 602 14.1.2.4.3 Weaknesses and competitive threats 602 14.1.3 ABBOTT 603 14.1.3.1 Business overview 603 14.1.3.2 Products/Services offered 604 14.1.3.3 Recent developments 607 14.1.3.3.1 Product launches and approvals 607 14.1.3.3.2 Deals 608 14.1.3.3.3 Expansions 609 14.1.3.4 MnM view 609 14.1.3.4.1 Key strengths 609 14.1.3.4.2 Strategic choices 609 14.1.3.4.3 Weakness and competitive threats 609 14.1.4 SIEMENS HEALTHINEERS AG 610 14.1.4.1 Business overview 610 14.1.4.2 Products/Services offered 612 14.1.4.3 Recent developments 614 14.1.4.3.1 Product launches and approvals 614 14.1.4.3.2 Deals 614 14.1.4.3.3 Expansions 616 14.1.4.4 MnM view 616 14.1.4.4.1 Key strengths 616 14.1.4.4.2 Strategic choices 616 14.1.4.4.3 Weaknesses and competitive threats 616 14.1.5 THERMO FISHER SCIENTIFIC INC. 617 14.1.5.1 Business overview 617 14.1.5.2 Products/Services offered 618 14.1.5.3 Recent developments 621 14.1.5.3.1 Product launches and approvals 621 14.1.5.3.2 Deals 622 14.1.5.3.3 Expansions 624 14.1.5.4 MnM view 624 14.1.5.4.1 Key strengths 624 14.1.5.4.2 Strategic choices 624 14.1.5.4.3 Weaknesses and competitive threats 625 14.1.6 ILLUMINA, INC. 626 14.1.6.1 Business overview 626 14.1.6.2 Products/Services offered 628 14.1.6.3 Recent developments 629 14.1.6.3.1 Product launches and approvals 629 14.1.6.3.2 Deals 630 14.1.6.3.3 Expansions 631 14.1.6.3.4 Other developments 632 14.1.7 HOLOGIC, INC. 633 14.1.7.1 Business overview 633 14.1.7.2 Products/Services offered 634 14.1.7.3 Recent developments 635 14.1.7.3.1 Product launches and approvals 635 14.1.7.3.2 Deals 636 14.1.7.3.3 Expansions 637 14.1.8 BIO-RAD LABORATORIES, INC. 638 14.1.8.1 Business overview 638 14.1.8.2 Products/Services offered 640 14.1.8.3 Recent developments 642 14.1.8.3.1 Product launches and approvals 642 14.1.8.3.2 Deals 643 14.1.9 BIOMÉRIEUX 644 14.1.9.1 Business overview 644 14.1.9.2 Products/Services offered 646 14.1.9.3 Recent developments 648 14.1.9.3.1 Product launches and approvals 648 14.1.9.3.2 Deals 649 14.1.9.3.3 Expansions 650 14.1.10 SYSMEX CORPORATION 651 14.1.10.1 Business overview 651 14.1.10.2 Products/Services offered 653 14.1.10.3 Recent developments 654 14.1.10.3.1 Product launches and approvals 654 14.1.10.3.2 Deals 655 14.1.10.3.3 Expansions 656 14.1.11 REVVITY 657 14.1.11.1 Business overview 657 14.1.11.2 Products/Services offered 659 14.1.11.3 Recent developments 660 14.1.11.3.1 Product launches and approvals 660 14.1.11.3.2 Deals 661 14.1.11.3.3 Other developments 661 14.1.12 BECTON, DICKINSON AND COMPANY 662 14.1.12.1 Business overview 662 14.1.12.2 Products/Services offered 663 14.1.12.3 Recent developments 666 14.1.12.3.1 Product launches and approvals 666 14.1.12.3.2 Deals 666 14.1.12.3.3 Expansions 667 14.1.13 AGILENT TECHNOLOGIES, INC. 668 14.1.13.1 Business overview 668 14.1.13.2 Products/Services offered 670 14.1.13.3 Recent developments 672 14.1.13.3.1 Product launches and approvals 672 14.1.13.3.2 Deals 673 14.1.13.3.3 Other developments 674 14.1.14 QIAGEN 675 14.1.14.1 Business overview 675 14.1.14.2 Products/Services offered 677 14.1.14.3 Recent developments 680 14.1.14.3.1 Product launches and approvals 680 14.1.14.3.2 Deals 682 14.1.15 DIASORIN S.P.A. 683 14.1.15.1 Business overview 683 14.1.15.2 Products/Services offered 685 14.1.15.3 Recent developments 687 14.1.15.3.1 Product launches and approvals 687 14.1.15.3.2 Deals 688 14.1.16 GRIFOLS, S.A. 689 14.1.16.1 Business overview 689 14.1.16.2 Products/Services offered 691 14.1.16.3 Recent developments 691 14.1.16.3.1 Product launches and approvals 691 14.1.16.3.2 Deals 692 14.1.17 WERFEN 693 14.1.17.1 Business overview 693 14.1.17.2 Products/Services offered 695 14.1.17.2.1 Deals 696 14.1.17.2.2 Expansions 697 14.1.18 QUIDELORTHO CORPORATION 698 14.1.18.1 Business overview 698 14.1.18.2 Products/Services offered 700 14.1.18.3 Recent developments 702 14.1.18.3.1 Product launches and approvals 702 14.1.18.3.2 Deals 703 14.1.18.3.3 Expansions 703 14.2 OTHER PLAYERS 704 14.2.1 DEVYSER 704 14.2.2 BIOSYNEX SA 705 14.2.3 SURMODICS, INC. 706 14.2.4 MENARINI SILICON BIOSYSTEMS 707 14.2.5 SPEEDX PTY. LTD. 708 14.2.6 GENSPEED BIOTECH GMBH 709 14.2.7 MERCK KGAA 710 14.2.8 CARIS LIFE SCIENCES 712 14.2.9 ARKRAY, INC. 713 14.2.10 ACCELERATE DIAGNOSTICS, INC. 714 14.2.11 CELLABS 715 14.2.12 J. MITRA & CO. PVT. LTD. 716 14.2.13 EPITOPE DIAGNOSTICS, INC. 717 14.2.14 BOSTER BIOLOGICAL TECHNOLOGY 718 14.2.15 ENZO BIOCHEM INC. 719 14.2.16 GENETIC SIGNATURES 720 14.2.17 SAVYON DIAGNOSTICS 721 14.2.18 TRIVITRON HEALTHCARE 722 14.2.19 MDXHEALTH 723 14.2.20 CREATIVE DIAGNOSTICS 724 14.2.21 INBIOS INTERNATIONAL, INC. 725 14.2.22 MACCURA BIOTECHNOLOGY CO., LTD. 726 14.2.23 LUYE LIFE SCIENCES GROUP 727 15 APPENDIX 728 15.1 DISCUSSION GUIDE 728 15.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 735 15.3 CUSTOMIZATION OPTIONS 737 15.4 RELATED REPORTS 738 15.5 AUTHOR DETAILS 739
圖表清單 List of Tables & Figures
TABLE 1 IN VITRO DIAGNOSTICS MARKET: INCLUSIONS AND EXCLUSIONS 59 TABLE 2 IN VITRO DIAGNOSTICS MARKET: RISK ASSESSMENT 74 TABLE 3 ESTIMATED INCREASE IN GERIATRIC POPULATION, BY REGION, 2022−2050 87 TABLE 4 IN VITRO DIAGNOSTICS MARKET: PRODUCT LAUNCHES, 2022−2024 89 TABLE 5 APPLICATION OF CANCER BIOMARKERS IN CLINICAL PRACTICE 92 TABLE 6 RECENT DEVELOPMENTS IN IVD MARKET, 2021–2023 95 TABLE 7 AVERAGE SELLING PRICE TREND OF IVD PRODUCTS, BY KEY PLAYER, 2022–2024 (USD) 99 TABLE 8 AVERAGE SELLING PRICE TREND OF CLINICAL CHEMISTRY ANALYZERS, BY REGION, 2022–2024 (USD) 100 TABLE 9 AVERAGE SELLING PRICE TREND OF IVD PRODUCTS, BY TYPE, 2022–2024 (USD) 101 TABLE 10 IN VITRO DIAGNOSTICS MARKET: ROLE OF COMPANIES IN ECOSYSTEM 105 TABLE 11 IN VITRO DIAGNOSTICS MARKET: INNOVATIONS AND PATENT REGISTRATIONS, 2022−2024 110 TABLE 12 IMPORT DATA FOR HS CODE 382200, BY COUNTRY, 2019–2024 (USD MILLION) 111 TABLE 13 EXPORT DATA FOR HS CODE 382200, BY COUNTRY, 2019–2024 (USD MILLION) 112 TABLE 14 IN VITRO DIAGNOSTICS MARKET: KEY CONFERENCES AND EVENTS, 2025−2026 112 TABLE 15 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 116 TABLE 16 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 116 TABLE 17 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 117 TABLE 18 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 117 TABLE 19 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 118 TABLE 20 US: CLASSIFICATION OF IVD DEVICES 118 TABLE 21 EUROPE: CLASSIFICATION OF IVD DEVICES 121 TABLE 22 JAPAN: CLASSIFICATION OF IVD REAGENTS IN JAPAN 123 TABLE 23 JAPAN: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 123 TABLE 24 CHINA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 123 TABLE 25 SOUTH KOREA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 124 TABLE 26 INDONESIA: REGISTRATION PROCESS FOR IVD DEVICES 125 TABLE 27 RUSSIA: CLASSIFICATION OF IVD DEVICES 126 TABLE 28 SAUDI ARABIA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 126 TABLE 29 MEXICO: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 128 TABLE 30 IN VITRO DIAGNOSTICS MARKET: PORTER’S FIVE FORCES ANALYSIS 129 TABLE 31 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF IVD PRODUCTS (%) 131 TABLE 32 KEY BUYING CRITERIA, BY PRODUCT & SERVICE 132 TABLE 33 US: OVERVIEW OF CERTAIN KEY CATEGORIES OF IVD DEVICES 134 TABLE 34 TARIFF RATES IMPOSED BY US, AS OF APRIL 2025 135 TABLE 35 COMPARATIVE ANALYSIS OF CENTRALIZED VS. DECENTRALIZED TESTING 137 TABLE 36 IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2030 (USD MILLION) 142 TABLE 37 IN VITRO DIAGNOSTICS MARKET FOR REAGENTS & KITS, BY REGION, 2022–2030 (USD MILLION) 144 TABLE 38 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR REAGENTS & KITS, BY COUNTRY, 2022–2030 (USD MILLION) 144 TABLE 39 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR REAGENTS & KITS, BY COUNTRY, 2022–2030 (USD MILLION) 145 TABLE 40 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR REAGENTS & KITS, BY COUNTRY, 2022–2030 (USD MILLION) 145 TABLE 41 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR REAGENTS & KITS, BY COUNTRY, 2022–2030 (USD MILLION) 146 TABLE 42 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR REAGENTS & KITS, BY COUNTRY, 2022–2030 (USD MILLION) 146 TABLE 43 KEY IVD INSTRUMENTS AVAILABLE WORLDWIDE 147 TABLE 44 IN VITRO DIAGNOSTICS MARKET FOR INSTRUMENTS, BY REGION, 2022–2030 (USD MILLION) 148 TABLE 45 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR INSTRUMENTS, BY COUNTRY, 2022–2030 (USD MILLION) 149 TABLE 46 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR INSTRUMENTS, BY COUNTRY, 2022–2030 (USD MILLION) 149 TABLE 47 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR INSTRUMENTS, BY COUNTRY, 2022–2030 (USD MILLION) 150 TABLE 48 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR INSTRUMENTS, BY COUNTRY, 2022–2030 (USD MILLION) 150 TABLE 49 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR INSTRUMENTS, BY COUNTRY, 2022–2030 (USD MILLION) 150 TABLE 50 KEY DATA MANAGEMENT SOFTWARE SOLUTIONS AVAILABLE WORLDWIDE 152 TABLE 51 IN VITRO DIAGNOSTICS MARKET FOR DATA MANAGEMENT SOFTWARE & SERVICES, BY REGION, 2022–2030 (USD MILLION) 153 TABLE 52 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR DATA MANAGEMENT SOFTWARE & SERVICES, BY COUNTRY, 2022–2030 (USD MILLION) 153 TABLE 53 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR DATA MANAGEMENT SOFTWARE & SERVICES, BY COUNTRY, 2022–2030 (USD MILLION) 154 TABLE 54 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR DATA MANAGEMENT SOFTWARE & SERVICES, BY COUNTRY, 2022–2030 (USD MILLION) 154 TABLE 55 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR DATA MANAGEMENT SOFTWARE & SERVICES, BY COUNTRY, 2022–2030 (USD MILLION) 155 TABLE 56 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR DATA MANAGEMENT SOFTWARE & SERVICES, BY COUNTRY, 2022–2030 (USD MILLION) 155 TABLE 57 IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION) 157 TABLE 58 KEY IMMUNOASSAY ANALYZERS AVAILABLE WORLDWIDE 158 TABLE 59 IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2022–2030 (USD MILLION) 159 TABLE 60 IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY REGION, 2022–2030 (USD MILLION) 160 TABLE 61 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY COUNTRY, 2022–2030 (USD MILLION) 160 TABLE 62 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY COUNTRY, 2022–2030 (USD MILLION) 161 TABLE 63 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY COUNTRY, 2022–2030 (USD MILLION) 161 TABLE 64 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY COUNTRY, 2022–2030 (USD MILLION) 162 TABLE 65 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY COUNTRY, 2022–2030 (USD MILLION) 162 TABLE 66 KEY ELISA ANALYZERS AVAILABLE WORLDWIDE 163 TABLE 67 IN VITRO DIAGNOSTICS MARKET FOR ENZYME-LINKED IMMUNOSORBENT ASSAYS, BY REGION, 2022–2030 (USD MILLION) 164 TABLE 68 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR ENZYME-LINKED IMMUNOSORBENT ASSAYS, BY COUNTRY, 2022–2030 (USD MILLION) 164 TABLE 69 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR ENZYME-LINKED IMMUNOSORBENT ASSAYS, BY COUNTRY, 2022–2030 (USD MILLION) 165 TABLE 70 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR ENZYME-LINKED IMMUNOSORBENT ASSAYS, BY COUNTRY, 2022–2030 (USD MILLION) 165 TABLE 71 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR ENZYME-LINKED IMMUNOSORBENT ASSAYS, BY COUNTRY, 2022–2030 (USD MILLION) 166 TABLE 72 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR ENZYME-LINKED IMMUNOSORBENT ASSAYS, BY COUNTRY, 2022–2030 (USD MILLION) 166 TABLE 73 KEY CHEMILUMINESCENCE IMMUNOASSAY SYSTEMS AVAILABLE WORLDWIDE 168 TABLE 74 IN VITRO DIAGNOSTICS MARKET FOR CHEMILUMINESCENCE IMMUNOASSAYS, BY REGION, 2022–2030 (USD MILLION) 168 TABLE 75 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR CHEMILUMINESCENCE IMMUNOASSAYS, BY COUNTRY, 2022–2030 (USD MILLION) 169 TABLE 76 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR CHEMILUMINESCENCE IMMUNOASSAYS, BY COUNTRY, 2022–2030 (USD MILLION) 169 TABLE 77 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR CHEMILUMINESCENCE IMMUNOASSAYS, BY COUNTRY, 2022–2030 (USD MILLION) 170 TABLE 78 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR CHEMILUMINESCENCE IMMUNOASSAYS, BY COUNTRY, 2022–2030 (USD MILLION) 170 TABLE 79 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR CHEMILUMINESCENCE IMMUNOASSAYS, BY COUNTRY, 2022–2030 (USD MILLION) 171 TABLE 80 IN VITRO DIAGNOSTICS MARKET FOR IMMUNOFLUORESCENCE ASSAYS, BY REGION, 2022–2030 (USD MILLION) 172 TABLE 81 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOFLUORESCENCE ASSAYS, BY COUNTRY, 2022–2030 (USD MILLION) 172 TABLE 82 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOFLUORESCENCE ASSAYS, BY COUNTRY, 2022–2030 (USD MILLION) 173 TABLE 83 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOFLUORESCENCE ASSAYS, BY COUNTRY, 2022–2030 (USD MILLION) 173 TABLE 84 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOFLUORESCENCE ASSAYS, BY COUNTRY, 2022–2030 (USD MILLION) 174 TABLE 85 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOFLUORESCENCE ASSAYS, BY COUNTRY, 2022–2030 (USD MILLION) 174 TABLE 86 KEY RAPID TESTS AVAILABLE WORLDWIDE 175 TABLE 87 IN VITRO DIAGNOSTICS MARKET FOR RAPID TESTS, BY REGION, 2022–2030 (USD MILLION) 176 TABLE 88 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR RAPID TESTS, BY COUNTRY, 2022–2030 (USD MILLION) 176 TABLE 89 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR RAPID TESTS, BY COUNTRY, 2022–2030 (USD MILLION) 177 TABLE 90 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR RAPID TESTS, BY COUNTRY, 2022–2030 (USD MILLION) 177 TABLE 91 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR RAPID TESTS, BY COUNTRY, 2022–2030 (USD MILLION) 178 TABLE 92 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR RAPID TESTS, BY COUNTRY, 2022–2030 (USD MILLION) 178 TABLE 93 IN VITRO DIAGNOSTICS MARKET FOR ENZYME-LINKED IMMUNOSPOT ASSAYS, BY REGION, 2022–2030 (USD MILLION) 179 TABLE 94 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR ENZYME-LINKED IMMUNOSPOT ASSAYS, BY COUNTRY, 2022–2030 (USD MILLION) 180 TABLE 95 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR ENZYME-LINKED IMMUNOSPOT ASSAYS, BY COUNTRY, 2022–2030 (USD MILLION) 180 TABLE 96 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR ENZYME-LINKED IMMUNOSPOT ASSAYS, BY COUNTRY, 2022–2030 (USD MILLION) 181 TABLE 97 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR ENZYME-LINKED IMMUNOSPOT ASSAYS, BY COUNTRY, 2022–2030 (USD MILLION) 181 TABLE 98 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR ENZYME-LINKED IMMUNOSPOT ASSAYS, BY COUNTRY, 2022–2030 (USD MILLION) 182 TABLE 99 KEY WESTERN BLOTTING SYSTEMS AVAILABLE WORLDWIDE 183 TABLE 100 IN VITRO DIAGNOSTICS MARKET FOR WESTERN BLOTTING, BY REGION, 2022–2030 (USD MILLION) 183 TABLE 101 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR WESTERN BLOTTING, BY COUNTRY, 2022–2030 (USD MILLION) 183 TABLE 102 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR WESTERN BLOTTING, BY COUNTRY, 2022–2030 (USD MILLION) 184 TABLE 103 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR WESTERN BLOTTING, BY COUNTRY, 2022–2030 (USD MILLION) 184 TABLE 104 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR WESTERN BLOTTING, BY COUNTRY, 2022–2030 (USD MILLION) 185 TABLE 105 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR WESTERN BLOTTING, BY COUNTRY, 2022–2030 (USD MILLION) 185 TABLE 106 IN VITRO DIAGNOSTICS MARKET FOR OTHER IMMUNOASSAY TECHNOLOGIES, BY REGION, 2022–2030 (USD MILLION) 186 TABLE 107 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR OTHER IMMUNOASSAY TECHNOLOGIES, BY COUNTRY, 2022–2030 (USD MILLION) 186 TABLE 108 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR OTHER IMMUNOASSAY TECHNOLOGIES, BY COUNTRY, 2022–2030 (USD MILLION) 187 TABLE 109 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR OTHER IMMUNOASSAY TECHNOLOGIES, BY COUNTRY, 2022–2030 (USD MILLION) 187 TABLE 110 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR OTHER IMMUNOASSAY TECHNOLOGIES, BY COUNTRY, 2022–2030 (USD MILLION) 188 TABLE 111 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR OTHER IMMUNOASSAY TECHNOLOGIES, BY COUNTRY, 2022–2030 (USD MILLION) 188 TABLE 112 CLINICAL CHEMISTRY ANALYZERS FOR HIGH AND MID-VOLUME LABORATORIES AVAILABLE WORLDWIDE 189 TABLE 113 CLINICAL CHEMISTRY ANALYZERS FOR LOW-VOLUME LABORATORIES AVAILABLE WORLDWIDE 190 TABLE 114 IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2022–2030 (USD MILLION) 191 TABLE 115 IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY REGION, 2022–2030 (USD MILLION) 191 TABLE 116 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY COUNTRY, 2022–2030 (USD MILLION) 192 TABLE 117 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY COUNTRY, 2022–2030 (USD MILLION) 192 TABLE 118 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY COUNTRY, 2022–2030 (USD MILLION) 193 TABLE 119 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY COUNTRY, 2022–2030 (USD MILLION) 193 TABLE 120 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY COUNTRY, 2022–2030 (USD MILLION) 194 TABLE 121 IN VITRO DIAGNOSTICS MARKET FOR BASIC METABOLIC PANELS, BY REGION, 2022–2030 (USD MILLION) 195 TABLE 122 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR BASIC METABOLIC PANELS, BY COUNTRY, 2022–2030 (USD MILLION) 195 TABLE 123 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR BASIC METABOLIC PANELS, BY COUNTRY, 2022–2030 (USD MILLION) 196 TABLE 124 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR BASIC METABOLIC PANELS, BY COUNTRY, 2022–2030 (USD MILLION) 196 TABLE 125 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR BASIC METABOLIC PANELS, BY COUNTRY, 2022–2030 (USD MILLION) 197 TABLE 126 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR BASIC METABOLIC PANELS, BY COUNTRY, 2022–2030 (USD MILLION) 197 TABLE 127 IN VITRO DIAGNOSTICS MARKET FOR LIVER PANELS, BY REGION, 2022–2030 (USD MILLION) 198 TABLE 128 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR LIVER PANELS, BY COUNTRY, 2022–2030 (USD MILLION) 199 TABLE 129 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR LIVER PANELS, BY COUNTRY, 2022–2030 (USD MILLION) 199 TABLE 130 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR LIVER PANELS, BY COUNTRY, 2022–2030 (USD MILLION) 200 TABLE 131 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR LIVER PANELS, BY COUNTRY, 2022–2030 (USD MILLION) 200 TABLE 132 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR LIVER PANELS, BY COUNTRY, 2022–2030 (USD MILLION) 201 TABLE 133 IN VITRO DIAGNOSTICS MARKET FOR RENAL PROFILES, BY REGION, 2022–2030 (USD MILLION) 202 TABLE 134 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR RENAL PROFILES, BY COUNTRY, 2022–2030 (USD MILLION) 202 TABLE 135 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR RENAL PROFILES, BY COUNTRY, 2022–2030 (USD MILLION) 203 TABLE 136 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR RENAL PROFILES, BY COUNTRY, 2022–2030 (USD MILLION) 203 TABLE 137 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR RENAL PROFILES, BY COUNTRY, 2022–2030 (USD MILLION) 204 TABLE 138 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR RENAL PROFILES, BY COUNTRY, 2022–2030 (USD MILLION) 204 TABLE 139 IN VITRO DIAGNOSTICS MARKET FOR LIPID PROFILES, BY REGION, 2022–2030 (USD MILLION) 205 TABLE 140 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR LIPID PROFILES, BY COUNTRY, 2022–2030 (USD MILLION) 206 TABLE 141 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR LIPID PROFILES, BY COUNTRY, 2022–2030 (USD MILLION) 206 TABLE 142 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR LIPID PROFILES, BY COUNTRY, 2022–2030 (USD MILLION) 207 TABLE 143 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR LIPID PROFILES, BY COUNTRY, 2022–2030 (USD MILLION) 207 TABLE 144 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR LIPID PROFILES, BY COUNTRY, 2022–2030 (USD MILLION) 208 TABLE 145 IN VITRO DIAGNOSTICS MARKET FOR THYROID FUNCTION PROFILES, BY REGION, 2022–2030 (USD MILLION) 209 TABLE 146 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR THYROID FUNCTION PROFILES, BY COUNTRY, 2022–2030 (USD MILLION) 209 TABLE 147 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR THYROID FUNCTION PROFILES, BY COUNTRY, 2022–2030 (USD MILLION) 210 TABLE 148 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR THYROID FUNCTION PROFILES, BY COUNTRY, 2022–2030 (USD MILLION) 210 TABLE 149 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR THYROID FUNCTION PROFILES, BY COUNTRY, 2022–2030 (USD MILLION) 211 TABLE 150 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR THYROID FUNCTION PROFILES, BY COUNTRY, 2022–2030 (USD MILLION) 211 TABLE 151 REFERENCE RANGES AND ABNORMAL CONDITIONS FOR KEY ELECTROLYTES 212 TABLE 152 IN VITRO DIAGNOSTICS MARKET FOR ELECTROLYTE PANELS, BY REGION, 2022–2030 (USD MILLION) 213 TABLE 153 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR ELECTROLYTE PANELS, BY COUNTRY, 2022–2030 (USD MILLION) 213 TABLE 154 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR ELECTROLYTE PANELS, BY COUNTRY, 2022–2030 (USD MILLION) 214 TABLE 155 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR ELECTROLYTE PANELS, BY COUNTRY, 2022–2030 (USD MILLION) 214 TABLE 156 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR ELECTROLYTE PANELS, BY COUNTRY, 2022–2030 (USD MILLION) 215 TABLE 157 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR ELECTROLYTE PANELS, BY COUNTRY, 2022–2030 (USD MILLION) 215 TABLE 158 IN VITRO DIAGNOSTICS MARKET FOR SPECIALTY CHEMICAL TESTS, BY REGION, 2022–2030 (USD MILLION) 216 TABLE 159 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR SPECIALTY CHEMICAL TESTS, BY COUNTRY, 2022–2030 (USD MILLION) 216 TABLE 160 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR SPECIALTY CHEMICAL TESTS, BY COUNTRY, 2022–2030 (USD MILLION) 217 TABLE 161 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR SPECIALTY CHEMICAL TESTS, BY COUNTRY, 2022–2030 (USD MILLION) 217 TABLE 162 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR SPECIALTY CHEMICAL TESTS, BY COUNTRY, 2022–2030 (USD MILLION) 218 TABLE 163 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR SPECIALTY CHEMICAL TESTS, BY COUNTRY, 2022–2030 (USD MILLION) 218 TABLE 164 KEY AUTOMATED MOLECULAR DIAGNOSTIC PLATFORMS AVAILABLE WORLDWIDE 219 TABLE 165 IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022–2030 (USD MILLION) 220 TABLE 166 IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY REGION, 2022–2030 (USD MILLION) 220 TABLE 167 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY COUNTRY, 2022–2030 (USD MILLION) 221 TABLE 168 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY COUNTRY, 2022–2030 (USD MILLION) 221 TABLE 169 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY COUNTRY, 2022–2030 (USD MILLION) 222 TABLE 170 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY COUNTRY, 2022–2030 (USD MILLION) 222 TABLE 171 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY COUNTRY, 2022–2030 (USD MILLION) 223 TABLE 172 KEY POLYMERASE CHAIN REACTION INSTRUMENTS AVAILABLE WORLDWIDE 224 TABLE 173 IN VITRO DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION, BY REGION, 2022–2030 (USD MILLION) 225 TABLE 174 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2022–2030 (USD MILLION) 225 TABLE 175 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2022–2030 (USD MILLION) 226 TABLE 176 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2022–2030 (USD MILLION) 226 TABLE 177 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2022–2030 (USD MILLION) 227 TABLE 178 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2022–2030 (USD MILLION) 227 TABLE 179 KEY ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY INSTRUMENTS AVAILABLE WORLDWIDE 229 TABLE 180 IN VITRO DIAGNOSTICS MARKET FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY, BY REGION, 2022–2030 (USD MILLION) 229 TABLE 181 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY, BY COUNTRY, 2022–2030 (USD MILLION) 229 TABLE 182 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY, BY COUNTRY, 2022–2030 (USD MILLION) 230 TABLE 183 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY, BY COUNTRY, 2022–2030 (USD MILLION) 230 TABLE 184 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY, BY COUNTRY, 2022–2030 (USD MILLION) 231 TABLE 185 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY, BY COUNTRY, 2022–2030 (USD MILLION) 231 TABLE 186 KEY NEXT-GENERATION SEQUENCING-BASED INSTRUMENTS AVAILABLE WORLDWIDE 232 TABLE 187 IN VITRO DIAGNOSTICS MARKET FOR DNA SEQUENCING & NEXT-GENERATION SEQUENCING, BY REGION, 2022–2030 (USD MILLION) 233 TABLE 188 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR DNA SEQUENCING & NEXT-GENERATION SEQUENCING, BY COUNTRY, 2022–2030 (USD MILLION) 233 TABLE 189 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR DNA SEQUENCING & NEXT-GENERATION SEQUENCING, BY COUNTRY, 2022–2030 (USD MILLION) 234 TABLE 190 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR DNA SEQUENCING & NEXT-GENERATION SEQUENCING, BY COUNTRY, 2022–2030 (USD MILLION) 234 TABLE 191 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR DNA SEQUENCING & NEXT-GENERATION SEQUENCING, BY COUNTRY, 2022–2030 (USD MILLION) 235 TABLE 192 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR DNA SEQUENCING & NEXT-GENERATION SEQUENCING, BY COUNTRY, 2022–2030 (USD MILLION) 235 TABLE 193 IN VITRO DIAGNOSTICS MARKET FOR IN SITU HYBRIDIZATION, BY REGION, 2022–2030 (USD MILLION) 236 TABLE 194 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR IN SITU HYBRIDIZATION, BY COUNTRY, 2022–2030 (USD MILLION) 236 TABLE 195 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR IN SITU HYBRIDIZATION, BY COUNTRY, 2022–2030 (USD MILLION) 237 TABLE 196 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR IN SITU HYBRIDIZATION, BY COUNTRY, 2022–2030 (USD MILLION) 237 TABLE 197 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR IN SITU HYBRIDIZATION, BY COUNTRY, 2022–2030 (USD MILLION) 238 TABLE 198 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR IN SITU HYBRIDIZATION, BY COUNTRY, 2022–2030 (USD MILLION) 238 TABLE 199 IN VITRO DIAGNOSTICS MARKET FOR DNA MICROARRAYS, BY REGION, 2022–2030 (USD MILLION) 239 TABLE 200 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR DNA MICROARRAYS, BY COUNTRY, 2022–2030 (USD MILLION) 239 TABLE 201 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR DNA MICROARRAYS, BY COUNTRY, 2022–2030 (USD MILLION) 240 TABLE 202 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR DNA MICROARRAYS, BY COUNTRY, 2022–2030 (USD MILLION) 240 TABLE 203 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR DNA MICROARRAYS, BY COUNTRY, 2022–2030 (USD MILLION) 241 TABLE 204 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR DNA MICROARRAYS, BY COUNTRY, 2022–2030 (USD MILLION) 241 TABLE 205 IN VITRO DIAGNOSTICS MARKET FOR OTHER MOLECULAR DIAGNOSTIC TECHNOLOGIES, BY REGION, 2022–2030 (USD MILLION) 242 TABLE 206 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR OTHER MOLECULAR DIAGNOSTIC TECHNOLOGIES, BY COUNTRY, 2022–2030 (USD MILLION) 242 TABLE 207 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR OTHER MOLECULAR DIAGNOSTIC TECHNOLOGIES, BY COUNTRY, 2022–2030 (USD MILLION) 243 TABLE 208 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR OTHER MOLECULAR DIAGNOSTIC TECHNOLOGIES, BY COUNTRY, 2022–2030 (USD MILLION) 243 TABLE 209 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR OTHER MOLECULAR DIAGNOSTIC TECHNOLOGIES, BY COUNTRY, 2022–2030 (USD MILLION) 244 TABLE 210 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR OTHER MOLECULAR DIAGNOSTIC TECHNOLOGIES, BY COUNTRY, 2022–2030 (USD MILLION) 244 TABLE 211 DIABETES-RELATED HEALTH EXPENDITURE PER PERSON, 2021 VS. 2030 VS. 2045 (USD) 245 TABLE 212 IN VITRO DIAGNOSTICS MARKET FOR GLUCOSE MONITORING, BY REGION, 2022–2030 (USD MILLION) 246 TABLE 213 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR GLUCOSE MONITORING, BY COUNTRY, 2022–2030 (USD MILLION) 246 TABLE 214 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR GLUCOSE MONITORING, BY COUNTRY, 2022–2030 (USD MILLION) 247 TABLE 215 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR GLUCOSE MONITORING, BY COUNTRY, 2022–2030 (USD MILLION) 247 TABLE 216 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR GLUCOSE MONITORING, BY COUNTRY, 2022–2030 (USD MILLION) 248 TABLE 217 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR GLUCOSE MONITORING, BY COUNTRY, 2022–2030 (USD MILLION) 248 TABLE 218 IN VITRO DIAGNOSTICS MARKET FOR HEMATOLOGY, BY REGION, 2022–2030 (USD MILLION) 249 TABLE 219 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR HEMATOLOGY, BY COUNTRY, 2022–2030 (USD MILLION) 249 TABLE 220 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR HEMATOLOGY, BY COUNTRY, 2022–2030 (USD MILLION) 250 TABLE 221 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR HEMATOLOGY, BY COUNTRY, 2022–2030 (USD MILLION) 250 TABLE 222 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR HEMATOLOGY, BY COUNTRY, 2022–2030 (USD MILLION) 251 TABLE 223 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR HEMATOLOGY, BY COUNTRY, 2022–2030 (USD MILLION) 251 TABLE 224 IN VITRO DIAGNOSTICS MARKET FOR MICROBIOLOGY, BY REGION, 2022–2030 (USD MILLION) 252 TABLE 225 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR MICROBIOLOGY, BY COUNTRY, 2022–2030 (USD MILLION) 252 TABLE 226 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR MICROBIOLOGY, BY COUNTRY, 2022–2030 (USD MILLION) 253 TABLE 227 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR MICROBIOLOGY, BY COUNTRY, 2022–2030 (USD MILLION) 253 TABLE 228 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR MICROBIOLOGY, BY COUNTRY, 2022–2030 (USD MILLION) 254 TABLE 229 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR MICROBIOLOGY, BY COUNTRY, 2022–2030 (USD MILLION) 254 TABLE 230 IN VITRO DIAGNOSTICS MARKET FOR COAGULATION & HEMOSTASIS, BY REGION, 2022–2030 (USD MILLION) 255 TABLE 231 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR COAGULATION & HEMOSTASIS, BY COUNTRY, 2022–2030 (USD MILLION) 256 TABLE 232 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR COAGULATION & HEMOSTASIS, BY COUNTRY, 2022–2030 (USD MILLION) 256 TABLE 233 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR COAGULATION & HEMOSTASIS, BY COUNTRY, 2022–2030 (USD MILLION) 257 TABLE 234 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR COAGULATION & HEMOSTASIS, BY COUNTRY, 2022–2030 (USD MILLION) 257 TABLE 235 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR COAGULATION & HEMOSTASIS, BY COUNTRY, 2022–2030 (USD MILLION) 258 TABLE 236 KEY BLOOD GAS ANALYZERS AVAILABLE WORLDWIDE 259 TABLE 237 IN VITRO DIAGNOSTICS MARKET FOR BLOOD GAS ANALYZERS, BY REGION, 2022–2030 (USD MILLION) 259 TABLE 238 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR BLOOD GAS ANALYZERS, BY COUNTRY, 2022–2030 (USD MILLION) 260 TABLE 239 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR BLOOD GAS ANALYZERS, BY COUNTRY, 2022–2030 (USD MILLION) 260 TABLE 240 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR BLOOD GAS ANALYZERS, BY COUNTRY, 2022–2030 (USD MILLION) 261 TABLE 241 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR BLOOD GAS ANALYZERS, BY COUNTRY, 2022–2030 (USD MILLION) 261 TABLE 242 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR BLOOD GAS ANALYZER, BY COUNTRY, 2022–2030 (USD MILLION) 262 TABLE 243 IN VITRO DIAGNOSTICS MARKET FOR URINALYSIS, BY REGION, 2022–2030 (USD MILLION) 263 TABLE 244 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR URINALYSIS, BY COUNTRY, 2022–2030 (USD MILLION) 263 TABLE 245 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR URINALYSIS, BY COUNTRY, 2022–2030 (USD MILLION) 264 TABLE 246 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR URINALYSIS, BY COUNTRY, 2022–2030 (USD MILLION) 264 TABLE 247 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR URINALYSIS, BY COUNTRY, 2022–2030 (USD MILLION) 265 TABLE 248 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR URINALYSIS, BY COUNTRY, 2022–2030 (USD MILLION) 265 TABLE 249 IN VITRO DIAGNOSTICS MARKET FOR CHROMATOGRAPHY & MASS SPECTROMETRY, BY REGION, 2022–2030 (USD MILLION) 266 TABLE 250 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR CHROMATOGRAPHY & MASS SPECTROMETRY, BY COUNTRY, 2022–2030 (USD MILLION) 267 TABLE 251 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR CHROMATOGRAPHY & MASS SPECTROMETRY, BY COUNTRY, 2022–2030 (USD MILLION) 267 TABLE 252 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR CHROMATOGRAPHY & MASS SPECTROMETRY, BY COUNTRY, 2022–2030 (USD MILLION) 268 TABLE 253 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR CHROMATOGRAPHY & MASS SPECTROMETRY, BY COUNTRY, 2022–2030 (USD MILLION) 268 TABLE 254 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR CHROMATOGRAPHY & MASS SPECTROMETRY, BY COUNTRY, 2022–2030 (USD MILLION) 269 TABLE 255 IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2022–2030 (USD MILLION) 271 TABLE 256 KEY BLOOD, SERUM, AND PLASMA SAMPLE TYPE-BASED PRODUCTS AVAILABLE WORLDWIDE 272 TABLE 257 IN VITRO DIAGNOSTICS MARKET FOR BLOOD, SERUM, AND PLASMA SPECIMENS, BY REGION, 2022–2030 (USD MILLION) 273 TABLE 258 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR BLOOD, SERUM, AND PLASMA SPECIMENS, BY COUNTRY, 2022–2030 (USD MILLION) 273 TABLE 259 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR BLOOD, SERUM, AND PLASMA SPECIMENS, BY COUNTRY, 2022–2030 (USD MILLION) 274 TABLE 260 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR BLOOD, SERUM, AND PLASMA SPECIMENS, BY COUNTRY, 2022–2030 (USD MILLION) 274 TABLE 261 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR BLOOD, SERUM, AND PLASMA SPECIMENS, BY COUNTRY, 2022–2030 (USD MILLION) 275 TABLE 262 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR BLOOD, SERUM, AND PLASMA SPECIMENS, BY COUNTRY, 2022–2030 (USD MILLION) 275 TABLE 263 IN VITRO DIAGNOSTICS MARKET FOR SALIVA SPECIMENS, BY REGION, 2022–2030 (USD MILLION) 276 TABLE 264 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR SALIVA SPECIMENS, BY COUNTRY, 2022–2030 (USD MILLION) 276 TABLE 265 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR SALIVA SPECIMENS, BY COUNTRY, 2022–2030 (USD MILLION) 277 TABLE 266 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR SALIVA SPECIMENS, BY COUNTRY, 2022–2030 (USD MILLION) 277 TABLE 267 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR SALIVA SPECIMENS, BY COUNTRY, 2022–2030 (USD MILLION) 278 TABLE 268 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR SALIVA SPECIMENS, BY COUNTRY, 2022–2030 (USD MILLION) 278 TABLE 269 KEY URINE SAMPLE TYPE-BASED PRODUCTS AVAILABLE WORLDWIDE 279 TABLE 270 IN VITRO DIAGNOSTICS MARKET FOR URINE SPECIMENS, BY REGION, 2022–2030 (USD MILLION) 280 TABLE 271 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR URINE SPECIMENS, BY COUNTRY, 2022–2030 (USD MILLION) 280 TABLE 272 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR URINE SPECIMENS, BY COUNTRY, 2022–2030 (USD MILLION) 281 TABLE 273 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR URINE SPECIMENS, BY COUNTRY, 2022–2030 (USD MILLION) 281 TABLE 274 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR URINE SPECIMENS, BY COUNTRY, 2022–2030 (USD MILLION) 282 TABLE 275 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR URINE SPECIMENS, BY COUNTRY, 2022–2030 (USD MILLION) 282 TABLE 276 IN VITRO DIAGNOSTICS MARKET FOR OTHER SPECIMENS, BY REGION, 2022–2030 (USD MILLION) 283 TABLE 277 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR OTHER SPECIMENS, BY COUNTRY, 2022–2030 (USD MILLION) 283 TABLE 278 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR OTHER SPECIMENS, BY COUNTRY, 2022–2030 (USD MILLION) 284 TABLE 279 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR OTHER SPECIMENS, BY COUNTRY, 2022–2030 (USD MILLION) 284 TABLE 280 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR OTHER SPECIMENS, BY COUNTRY, 2022–2030 (USD MILLION) 285 TABLE 281 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR OTHER SPECIMENS, BY COUNTRY, 2022–2030 (USD MILLION) 285 TABLE 282 IN VITRO DIAGNOSTICS MARKET, BY SITE OF TESTING, 2022–2030 (USD MILLION) 287 TABLE 283 IN VITRO DIAGNOSTICS MARKET FOR LABORATORY TESTS, BY TECHNOLOGY, 2022–2030 (USD MILLION) 290 TABLE 284 IN VITRO DIAGNOSTICS MARKET FOR LABORATORY TESTS, BY REGION, 2022–2030 (USD MILLION) 290 TABLE 285 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR LABORATORY TESTS, BY COUNTRY, 2022–2030 (USD MILLION) 291 TABLE 286 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR LABORATORY TESTS, BY COUNTRY, 2022–2030 (USD MILLION) 291 TABLE 287 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR LABORATORY TESTS, BY COUNTRY, 2022–2030 (USD MILLION) 292 TABLE 288 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR LABORATORY TESTS, BY COUNTRY, 2022–2030 (USD MILLION) 292 TABLE 289 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR LABORATORY TESTS, BY COUNTRY, 2022–2030 (USD MILLION) 293 TABLE 290 IN VITRO DIAGNOSTICS MARKET FOR POINT-OF-CARE TESTS, BY TECHNOLOGY, 2022–2030 (USD MILLION) 295 TABLE 291 IN VITRO DIAGNOSTICS MARKET FOR POINT-OF-CARE TESTS, BY REGION, 2022–2030 (USD MILLION) 296 TABLE 292 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR POINT-OF-CARE TESTS, BY COUNTRY, 2022–2030 (USD MILLION) 296 TABLE 293 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR POINT-OF-CARE TESTS, BY COUNTRY, 2022–2030 (USD MILLION) 297 TABLE 294 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR POINT-OF-CARE TESTS, BY COUNTRY, 2022–2030 (USD MILLION) 297 TABLE 295 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR POINT-OF-CARE TESTS, BY COUNTRY, 2022–2030 (USD MILLION) 298 TABLE 296 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR POINT-OF-CARE TESTS, BY COUNTRY, 2022–2030 (USD MILLION) 298 TABLE 297 IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2022–2030 (USD MILLION) 300 TABLE 298 IN VITRO DIAGNOSTICS MARKET FOR INFECTIOUS DISEASES, BY REGION, 2022–2030 (USD MILLION) 302 TABLE 299 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022–2030 (USD MILLION) 302 TABLE 300 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022–2030 (USD MILLION) 303 TABLE 301 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022–2030 (USD MILLION) 303 TABLE 302 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022–2030 (USD MILLION) 304 TABLE 303 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022–2030 (USD MILLION) 304 TABLE 304 INCREASING INCIDENCE OF CANCER, BY REGION, 2022 VS. 2040 305 TABLE 305 LIST OF APPROVED COMPANION DIAGNOSTIC DEVICES, 2022–2024 306 TABLE 306 IN VITRO DIAGNOSTICS MARKET FOR ONCOLOGY, BY REGION, 2022–2030 (USD MILLION) 306 TABLE 307 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR ONCOLOGY, BY COUNTRY, 2022–2030 (USD MILLION) 306 TABLE 308 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR ONCOLOGY, BY COUNTRY, 2022–2030 (USD MILLION) 307 TABLE 309 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR ONCOLOGY, BY COUNTRY, 2022–2030 (USD MILLION) 307 TABLE 310 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR ONCOLOGY, BY COUNTRY, 2022–2030 (USD MILLION) 308 TABLE 311 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR ONCOLOGY, BY COUNTRY, 2022–2030 (USD MILLION) 308 TABLE 312 IN VITRO DIAGNOSTICS MARKET FOR ENDOCRINOLOGY, BY REGION, 2022–2030 (USD MILLION) 309 TABLE 313 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR ENDOCRINOLOGY, BY COUNTRY, 2022–2030 (USD MILLION) 310 TABLE 314 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR ENDOCRINOLOGY, BY COUNTRY, 2022–2030 (USD MILLION) 310 TABLE 315 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR ENDOCRINOLOGY, BY COUNTRY, 2022–2030 (USD MILLION) 311 TABLE 316 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR ENDOCRINOLOGY, BY COUNTRY, 2022–2030 (USD MILLION) 311 TABLE 317 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR ENDOCRINOLOGY, BY COUNTRY, 2022–2030 (USD MILLION) 312 TABLE 318 IN VITRO DIAGNOSTICS MARKET FOR CARDIOLOGY, BY REGION, 2022–2030 (USD MILLION) 313 TABLE 319 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR CARDIOLOGY, BY COUNTRY, 2022–2030 (USD MILLION) 313 TABLE 320 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR CARDIOLOGY, BY COUNTRY, 2022–2030 (USD MILLION) 314 TABLE 321 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR CARDIOLOGY, BY COUNTRY, 2022–2030 (USD MILLION) 314 TABLE 322 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR CARDIOLOGY, BY COUNTRY, 2022–2030 (USD MILLION) 315 TABLE 323 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR CARDIOLOGY, BY COUNTRY, 2022–2030 (USD MILLION) 315 TABLE 324 IN VITRO DIAGNOSTICS MARKET FOR BLOOD SCREENING, BY REGION, 2022–2030 (USD MILLION) 316 TABLE 325 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR BLOOD SCREENING, BY COUNTRY, 2022–2030 (USD MILLION) 317 TABLE 326 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR BLOOD SCREENING, BY COUNTRY, 2022–2030 (USD MILLION) 317 TABLE 327 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR BLOOD SCREENING, BY COUNTRY, 2022–2030 (USD MILLION) 318 TABLE 328 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR BLOOD SCREENING, BY COUNTRY, 2022–2030 (USD MILLION) 318 TABLE 329 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR BLOOD SCREENING, BY COUNTRY, 2022–2030 (USD MILLION) 319 TABLE 330 IN VITRO DIAGNOSTICS MARKET FOR GENETIC TESTING, BY REGION, 2022–2030 (USD MILLION) 320 TABLE 331 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR GENETIC TESTING, BY COUNTRY, 2022–2030 (USD MILLION) 320 TABLE 332 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR GENETIC TESTING, BY COUNTRY, 2022–2030 (USD MILLION) 321 TABLE 333 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR GENETIC TESTING, BY COUNTRY, 2022–2030 (USD MILLION) 321 TABLE 334 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR GENETIC TESTING, BY COUNTRY, 2022–2030 (USD MILLION) 322 TABLE 335 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR GENETIC TESTING, BY COUNTRY, 2022–2030 (USD MILLION) 322 TABLE 336 IN VITRO DIAGNOSTICS MARKET FOR AUTOIMMUNE DISEASES, BY REGION, 2022–2030 (USD MILLION) 324 TABLE 337 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2022–2030 (USD MILLION) 324 TABLE 338 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2022–2030 (USD MILLION) 325 TABLE 339 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2022–2030 (USD MILLION) 325 TABLE 340 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2022–2030 (USD MILLION) 326 TABLE 341 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2022–2030 (USD MILLION) 326 TABLE 342 IN VITRO DIAGNOSTICS MARKET FOR ALLERGY DIAGNOSTICS, BY REGION, 2022–2030 (USD MILLION) 327 TABLE 343 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR ALLERGY DIAGNOSTICS, BY COUNTRY, 2022–2030 (USD MILLION) 328 TABLE 344 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR ALLERGY DIAGNOSTICS, BY COUNTRY, 2022–2030 (USD MILLION) 328 TABLE 345 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR ALLERGY DIAGNOSTICS, BY COUNTRY, 2022–2030 (USD MILLION) 329 TABLE 346 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR ALLERGY DIAGNOSTICS, BY COUNTRY, 2022–2030 (USD MILLION) 329 TABLE 347 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR ALLERGY DIAGNOSTICS, BY COUNTRY, 2022–2030 (USD MILLION) 330 TABLE 348 KEY PRODUCTS FOR DRUG MONITORING WORLDWIDE 331 TABLE 349 KEY IVD PRODUCTS FOR DRUG TESTING WORLDWIDE 331 TABLE 350 IN VITRO DIAGNOSTICS MARKET FOR DRUG MONITORING & TESTING, BY REGION, 2022–2030 (USD MILLION) 332 TABLE 351 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR DRUG MONITORING & TESTING, BY COUNTRY, 2022–2030 (USD MILLION) 332 TABLE 352 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR DRUG MONITORING & TESTING, BY COUNTRY, 2022–2030 (USD MILLION) 333 TABLE 353 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR DRUG MONITORING & TESTING, BY COUNTRY, 2022–2030 (USD MILLION) 333 TABLE 354 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR DRUG MONITORING & TESTING, BY COUNTRY, 2022–2030 (USD MILLION) 334 TABLE 355 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR DRUG MONITORING & TESTING, BY COUNTRY, 2022–2030 (USD MILLION) 334 TABLE 356 KEY PRODUCTS FOR BONE & MINERAL DISORDERS WORLDWIDE 336 TABLE 357 IN VITRO DIAGNOSTICS MARKET FOR BONE & MINERAL DISORDERS, BY REGION, 2022–2030 (USD MILLION) 336 TABLE 358 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR BONE & MINERAL DISORDERS, BY COUNTRY, 2022–2030 (USD MILLION) 336 TABLE 359 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR BONE & MINERAL DISORDERS, BY COUNTRY, 2022–2030 (USD MILLION) 337 TABLE 360 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR BONE & MINERAL DISORDERS, BY COUNTRY, 2022–2030 (USD MILLION) 337 TABLE 361 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR BONE & MINERAL DISORDERS, BY COUNTRY, 2022–2030 (USD MILLION) 338 TABLE 362 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR BONE & MINERAL DISORDERS, BY COUNTRY, 2022–2030 (USD MILLION) 338 TABLE 363 IN VITRO DIAGNOSTICS MARKET FOR COAGULATION TESTING, BY REGION, 2022–2030 (USD MILLION) 339 TABLE 364 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR COAGULATION TESTING, BY COUNTRY, 2022–2030 (USD MILLION) 339 TABLE 365 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR COAGULATION TESTING, BY COUNTRY, 2022–2030 (USD MILLION) 340 TABLE 366 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR COAGULATION TESTING, BY COUNTRY, 2022–2030 (USD MILLION) 340 TABLE 367 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR COAGULATION TESTING, BY COUNTRY, 2022–2030 (USD MILLION) 341 TABLE 368 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR COAGULATION TESTING, BY COUNTRY, 2022–2030 (USD MILLION) 341 TABLE 369 IN VITRO DIAGNOSTICS MARKET FOR BLOOD GROUP TYPING, BY REGION, 2022–2030 (USD MILLION) 342 TABLE 370 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR BLOOD GROUP TYPING, BY COUNTRY, 2022–2030 (USD MILLION) 343 TABLE 371 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR BLOOD GROUP TYPING, BY COUNTRY, 2022–2030 (USD MILLION) 343 TABLE 372 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR BLOOD GROUP TYPING, BY COUNTRY, 2022–2030 (USD MILLION) 344 TABLE 373 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR BLOOD GROUP TYPING, BY COUNTRY, 2022–2030 (USD MILLION) 344 TABLE 374 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR BLOOD GROUP TYPING, BY COUNTRY, 2022–2030 (USD MILLION) 345 TABLE 375 IN VITRO DIAGNOSTICS MARKET FOR OTHER APPLICATIONS, BY REGION, 2022–2030 (USD MILLION) 346 TABLE 376 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022–2030 (USD MILLION) 346 TABLE 377 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022–2030 (USD MILLION) 347 TABLE 378 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022–2030 (USD MILLION) 347 TABLE 379 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022–2030 (USD MILLION) 348 TABLE 380 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022–2030 (USD MILLION) 348 TABLE 381 IN VITRO DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION) 350 TABLE 382 IN VITRO DIAGNOSTICS MARKET FOR HOSPITALS & CLINICS, BY REGION, 2022–2030 (USD MILLION) 352 TABLE 383 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2022–2030 (USD MILLION) 352 TABLE 384 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2022–2030 (USD MILLION) 353 TABLE 385 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2022–2030 (USD MILLION) 353 TABLE 386 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2022–2030 (USD MILLION) 354 TABLE 387 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2022–2030 (USD MILLION) 354 TABLE 388 IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2022–2030 (USD MILLION) 355 TABLE 389 IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY REGION, 2022–2030 (USD MILLION) 355 TABLE 390 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY COUNTRY, 2022–2030 (USD MILLION) 356 TABLE 391 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY COUNTRY, 2022–2030 (USD MILLION) 356 TABLE 392 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY COUNTRY, 2022–2030 (USD MILLION) 357 TABLE 393 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY COUNTRY, 2022–2030 (USD MILLION) 357 TABLE 394 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY COUNTRY, 2022–2030 (USD MILLION) 358 TABLE 395 IN VITRO DIAGNOSTICS MARKET FOR LARGE REFERENCE LABORATORIES, BY REGION, 2022–2030 (USD MILLION) 359 TABLE 396 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR LARGE REFERENCE LABORATORIES, BY COUNTRY, 2022–2030 (USD MILLION) 359 TABLE 397 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR LARGE REFERENCE LABORATORIES, BY COUNTRY, 2022–2030 (USD MILLION) 360 TABLE 398 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR LARGE REFERENCE LABORATORIES, BY COUNTRY, 2022–2030 (USD MILLION) 360 TABLE 399 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR LARGE REFERENCE LABORATORIES, BY COUNTRY, 2022–2030 (USD MILLION) 361 TABLE 400 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR LARGE REFERENCE LABORATORIES, BY COUNTRY, 2022–2030 (USD MILLION) 361 TABLE 401 IN VITRO DIAGNOSTICS MARKET FOR SMALL AND MEDIUM-SIZED LABORATORIES, BY REGION, 2022–2030 (USD MILLION) 362 TABLE 402 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR SMALL AND MEDIUM-SIZED LABORATORIES, BY COUNTRY, 2022–2030 (USD MILLION) 362 TABLE 403 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR SMALL AND MEDIUM-SIZED LABORATORIES, BY COUNTRY, 2022–2030 (USD MILLION) 363 TABLE 404 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR SMALL AND MEDIUM-SIZED LABORATORIES, BY COUNTRY, 2022–2030 (USD MILLION) 363 TABLE 405 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR SMALL AND MEDIUM-SIZED LABORATORIES, BY COUNTRY, 2022–2030 (USD MILLION) 364 TABLE 406 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR SMALL AND MEDIUM-SIZED LABORATORIES, BY COUNTRY, 2022–2030 (USD MILLION) 364 TABLE 407 IN VITRO DIAGNOSTICS MARKET FOR BLOOD BANKS, BY REGION, 2022–2030 (USD MILLION) 365 TABLE 408 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR BLOOD BANKS, BY COUNTRY, 2022–2030 (USD MILLION) 366 TABLE 409 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR BLOOD BANKS, BY COUNTRY, 2022–2030 (USD MILLION) 366 TABLE 410 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR BLOOD BANKS, BY COUNTRY, 2022–2030 (USD MILLION) 367 TABLE 411 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR BLOOD BANKS, BY COUNTRY, 2022–2030 (USD MILLION) 367 TABLE 412 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR BLOOD BANKS, BY COUNTRY, 2022–2030 (USD MILLION) 368 TABLE 413 IN VITRO DIAGNOSTICS MARKET FOR HOME CARE SETTINGS, BY REGION, 2022–2030 (USD MILLION) 369 TABLE 414 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2022–2030 (USD MILLION) 370 TABLE 415 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2022–2030 (USD MILLION) 370 TABLE 416 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2022–2030 (USD MILLION) 371 TABLE 417 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2022–2030 (USD MILLION) 371 TABLE 418 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2022–2030 (USD MILLION) 372 TABLE 419 IN VITRO DIAGNOSTICS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2022–2030 (USD MILLION) 373 TABLE 420 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022–2030 (USD MILLION) 373 TABLE 421 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022–2030 (USD MILLION) 374 TABLE 422 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022–2030 (USD MILLION) 374 TABLE 423 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022–2030 (USD MILLION) 375 TABLE 424 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022–2030 (USD MILLION) 375 TABLE 425 IN VITRO DIAGNOSTICS MARKET FOR ACADEMIC INSTITUTES, BY REGION, 2022–2030 (USD MILLION) 376 TABLE 426 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2022–2030 (USD MILLION) 376 TABLE 427 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2022–2030 (USD MILLION) 377 TABLE 428 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2022–2030 (USD MILLION) 377 TABLE 429 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2022–2030 (USD MILLION) 378 TABLE 430 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2022–2030 (USD MILLION) 378 TABLE 431 IN VITRO DIAGNOSTICS MARKET FOR OTHER END USERS, BY REGION, 2022–2030 (USD MILLION) 379 TABLE 432 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2022–2030 (USD MILLION) 379 TABLE 433 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2022–2030 (USD MILLION) 380 TABLE 434 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2022–2030 (USD MILLION) 380 TABLE 435 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2022–2030 (USD MILLION) 381 TABLE 436 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2022–2030 (USD MILLION) 381 TABLE 437 IN VITRO DIAGNOSTICS MARKET, BY REGION, 2022–2030 (USD MILLION) 383 TABLE 438 NORTH AMERICA: KEY MACROECONOMIC INDICATORS 384 TABLE 439 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 386 TABLE 440 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2030 (USD MILLION) 386 TABLE 441 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION) 387 TABLE 442 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2022–2030 (USD MILLION) 388 TABLE 443 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2022–2030 (USD MILLION) 388 TABLE 444 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022–2030 (USD MILLION) 389 TABLE 445 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2022–2030 (USD MILLION) 389 TABLE 446 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION) 390 TABLE 447 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2022–2030 (USD MILLION) 390 TABLE 448 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION) 391 TABLE 449 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2022–2030 (USD MILLION) 391 TABLE 450 US: KEY MACROECONOMIC INDICATORS 393 TABLE 451 US: NUMBER OF IN VITRO DIAGNOSTICS TESTS CONDUCTED, 2022–2030 (BILLION) 393 TABLE 452 US: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2030 (USD MILLION) 393 TABLE 453 US: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION) 394 TABLE 454 US: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2022–2030 (USD MILLION) 394 TABLE 455 US: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2022–2030 (USD MILLION) 395 TABLE 456 US: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022–2030 (USD MILLION) 395 TABLE 457 US: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2022–2030 (USD MILLION) 396 TABLE 458 US: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION) 396 TABLE 459 US: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2022–2030 (USD MILLION) 397 TABLE 460 US: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION) 398 TABLE 461 US: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2022–2030 (USD MILLION) 398 TABLE 462 CANADA: ESTIMATED PREVALENCE OF DIABETES, 2024 VS. 2034 399 TABLE 463 CANADA: KEY MACROECONOMIC INDICATORS 400 TABLE 464 CANADA: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2030 (USD MILLION) 400 TABLE 465 CANADA: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION) 401 TABLE 466 CANADA: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2022–2030 (USD MILLION) 401 TABLE 467 CANADA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2022–2030 (USD MILLION) 402 TABLE 468 CANADA: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022–2030 (USD MILLION) 402 TABLE 469 CANADA: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2022–2030 (USD MILLION) 403 TABLE 470 CANADA: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION) 403 TABLE 471 CANADA: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2022–2030 (USD MILLION) 404 TABLE 472 CANADA: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION) 404 TABLE 473 CANADA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2022–2030 (USD MILLION) 405 TABLE 474 EUROPE: KEY MACROECONOMIC INDICATORS 406 TABLE 475 EUROPE: IN VITRO DIAGNOSTICS MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 407 TABLE 476 EUROPE: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2030 (USD MILLION) 407 TABLE 477 EUROPE: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION) 408 TABLE 478 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2022–2030 (USD MILLION) 408 TABLE 479 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2022–2030 (USD MILLION) 409 TABLE 480 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022–2030 (USD MILLION) 409 TABLE 481 EUROPE: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2022–2030 (USD MILLION) 410 TABLE 482 EUROPE: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION) 410 TABLE 483 EUROPE: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2022–2030 (USD MILLION) 411 TABLE 484 EUROPE: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION) 412 TABLE 485 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2022–2030 (USD MILLION) 412 TABLE 486 GERMANY: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2030 (USD MILLION) 414 TABLE 487 GERMANY: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION) 414 TABLE 488 GERMANY: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2022–2030 (USD MILLION) 415 TABLE 489 GERMANY: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2022–2030 (USD MILLION) 415 TABLE 490 GERMANY: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022–2030 (USD MILLION) 416 TABLE 491 GERMANY: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2022–2030 (USD MILLION) 416 TABLE 492 GERMANY: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION) 417 TABLE 493 GERMANY: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2022–2030 (USD MILLION) 417 TABLE 494 GERMANY: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION) 418 TABLE 495 GERMANY: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2022–2030 (USD MILLION) 418 TABLE 496 FRANCE: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2030 (USD MILLION) 419 TABLE 497 FRANCE: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION) 420 TABLE 498 FRANCE: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2022–2030 (USD MILLION) 420 TABLE 499 FRANCE: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2022–2030 (USD MILLION) 421 TABLE 500 FRANCE: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022–2030 (USD MILLION) 421 TABLE 501 FRANCE: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2022–2030 (USD MILLION) 422 TABLE 502 FRANCE: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION) 422 TABLE 503 FRANCE: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2022–2030 (USD MILLION) 423 TABLE 504 FRANCE: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION) 423 TABLE 505 FRANCE: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2022–2030 (USD MILLION) 424 TABLE 506 UK: KEY MACROECONOMIC INDICATORS 425 TABLE 507 UK: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2030 (USD MILLION) 426 TABLE 508 UK: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION) 426 TABLE 509 UK: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2022–2030 (USD MILLION) 427 TABLE 510 UK: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2022–2030 (USD MILLION) 427 TABLE 511 UK: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022–2030 (USD MILLION) 428 TABLE 512 UK: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2022–2030 (USD MILLION) 428 TABLE 513 UK: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION) 429 TABLE 514 UK: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2022–2030 (USD MILLION) 429 TABLE 515 UK: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION) 430 TABLE 516 UK: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2022–2030 (USD MILLION) 430 TABLE 517 ITALY: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2030 (USD MILLION) 431 TABLE 518 ITALY: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION) 432 TABLE 519 ITALY: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2022–2030 (USD MILLION) 432 TABLE 520 ITALY: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2022–2030 (USD MILLION) 433 TABLE 521 ITALY: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022–2030 (USD MILLION) 433 TABLE 522 ITALY: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2022–2030 (USD MILLION) 434 TABLE 523 ITALY: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION) 434 TABLE 524 ITALY: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2022–2030 (USD MILLION) 435 TABLE 525 ITALY: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION) 435 TABLE 526 ITALY: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2022–2030 (USD MILLION) 436 TABLE 527 SPAIN: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2030 (USD MILLION) 437 TABLE 528 SPAIN: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION) 437 TABLE 529 SPAIN: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2022–2030 (USD MILLION) 438 TABLE 530 SPAIN: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2022–2030 (USD MILLION) 438 TABLE 531 SPAIN: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022–2030 (USD MILLION) 439 TABLE 532 SPAIN: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2022–2030 (USD MILLION) 439 TABLE 533 SPAIN: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION) 440 TABLE 534 SPAIN: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2022–2030 (USD MILLION) 440 TABLE 535 SPAIN: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION) 441 TABLE 536 SPAIN: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2022–2030 (USD MILLION) 441 TABLE 537 RUSSIA: KEY MACROECONOMIC INDICATORS 442 TABLE 538 RUSSIA: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2030 (USD MILLION) 442 TABLE 539 RUSSIA: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION) 443 TABLE 540 RUSSIA: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2022–2030 (USD MILLION) 443 TABLE 541 RUSSIA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2022–2030 (USD MILLION) 444 TABLE 542 RUSSIA: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022–2030 (USD MILLION) 444 TABLE 543 RUSSIA: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2022–2030 (USD MILLION) 445 TABLE 544 RUSSIA: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION) 445 TABLE 545 RUSSIA: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2022–2030 (USD MILLION) 446 TABLE 546 RUSSIA: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION) 446 TABLE 547 RUSSIA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2022–2030 (USD MILLION) 447 TABLE 548 SWITZERLAND: KEY MACROECONOMIC INDICATORS 448 TABLE 549 SWITZERLAND: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2030 (USD MILLION) 448 TABLE 550 SWITZERLAND: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION) 449 TABLE 551 SWITZERLAND: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2022–2030 (USD MILLION) 449 TABLE 552 SWITZERLAND: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2022–2030 (USD MILLION) 450 TABLE 553 SWITZERLAND: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022–2030 (USD MILLION) 450 TABLE 554 SWITZERLAND: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2022–2030 (USD MILLION) 451 TABLE 555 SWITZERLAND: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION) 451 TABLE 556 SWITZERLAND: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2022–2030 (USD MILLION) 452 TABLE 557 SWITZERLAND: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION) 453 TABLE 558 SWITZERLAND: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2022–2030 (USD MILLION) 453 TABLE 559 REST OF EUROPE: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2030 (USD MILLION) 454 TABLE 560 REST OF EUROPE: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION) 455 TABLE 561 REST OF EUROPE: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2022–2030 (USD MILLION) 455 TABLE 562 REST OF EUROPE: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2022–2030 (USD MILLION) 456 TABLE 563 REST OF EUROPE: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022–2030 (USD MILLION) 456 TABLE 564 REST OF EUROPE: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2022–2030 (USD MILLION) 457 TABLE 565 REST OF EUROPE: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION) 457 TABLE 566 REST OF EUROPE: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2022–2030 (USD MILLION) 458 TABLE 567 REST OF EUROPE: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION) 458 TABLE 568 REST OF EUROPE: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2022–2030 (USD MILLION) 459 TABLE 569 ASIA PACIFIC: KEY MACROECONOMIC INDICATORS 460 TABLE 570 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 462 TABLE 571 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2030 (USD MILLION) 462 TABLE 572 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION) 463 TABLE 573 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2022–2030 (USD MILLION) 464 TABLE 574 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2022–2030 (USD MILLION) 464 TABLE 575 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022–2030 (USD MILLION) 465 TABLE 576 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2022–2030 (USD MILLION) 465 TABLE 577 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION) 466 TABLE 578 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2022–2030 (USD MILLION) 466 TABLE 579 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION) 467 TABLE 580 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2022–2030 (USD MILLION) 467 TABLE 581 JAPAN: KEY MACROECONOMIC INDICATORS 468 TABLE 582 JAPAN: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2030 (USD MILLION) 469 TABLE 583 JAPAN: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION) 469 TABLE 584 JAPAN: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2022–2030 (USD MILLION) 470 TABLE 585 JAPAN: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2022–2030 (USD MILLION) 470 TABLE 586 JAPAN: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022–2030 (USD MILLION) 471 TABLE 587 JAPAN: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2022–2030 (USD MILLION) 471 TABLE 588 JAPAN: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION) 472 TABLE 589 JAPAN: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2022–2030 (USD MILLION) 472 TABLE 590 JAPAN: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION) 473 TABLE 591 JAPAN: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2022–2030 (USD MILLION) 473 TABLE 592 CHINA: KEY MACROECONOMIC INDICATORS 474 TABLE 593 CHINA: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2030 (USD MILLION) 474 TABLE 594 CHINA: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION) 475 TABLE 595 CHINA: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2022–2030 (USD MILLION) 475 TABLE 596 CHINA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2022–2030 (USD MILLION) 476 TABLE 597 CHINA: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022–2030 (USD MILLION) 476 TABLE 598 CHINA: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2022–2030 (USD MILLION) 477 TABLE 599 CHINA: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION) 477 TABLE 600 CHINA: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2022–2030 (USD MILLION) 478 TABLE 601 CHINA: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION) 478 TABLE 602 CHINA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2022–2030 (USD MILLION) 479 TABLE 603 INDIA: KEY MACROECONOMIC INDICATORS 480 TABLE 604 INDIA: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2030 (USD MILLION) 480 TABLE 605 INDIA: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION) 481 TABLE 606 INDIA: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2022–2030 (USD MILLION) 481 TABLE 607 INDIA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2022–2030 (USD MILLION) 482 TABLE 608 INDIA: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022–2030 (USD MILLION) 482 TABLE 609 INDIA: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2022–2030 (USD MILLION) 483 TABLE 610 INDIA: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION) 483 TABLE 611 INDIA: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2022–2030 (USD MILLION) 484 TABLE 612 INDIA: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION) 484 TABLE 613 INDIA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2022–2030 (USD MILLION) 485 TABLE 614 SOUTH KOREA: KEY MACROECONOMIC INDICATORS 486 TABLE 615 SOUTH KOREA: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2030 (USD MILLION) 486 TABLE 616 SOUTH KOREA: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION) 487 TABLE 617 SOUTH KOREA: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2022–2030 (USD MILLION) 487 TABLE 618 SOUTH KOREA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2022–2030 (USD MILLION) 488 TABLE 619 SOUTH KOREA: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022–2030 (USD MILLION) 488 TABLE 620 SOUTH KOREA: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2022–2030 (USD MILLION) 489 TABLE 621 SOUTH KOREA: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION) 489 TABLE 622 SOUTH KOREA: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2022–2030 (USD MILLION) 490 TABLE 623 SOUTH KOREA: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION) 491 TABLE 624 SOUTH KOREA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2022–2030 (USD MILLION) 491 TABLE 625 AUSTRALIA: KEY MACROECONOMIC INDICATORS 492 TABLE 626 AUSTRALIA: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2030 (USD MILLION) 492 TABLE 627 AUSTRALIA: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION) 493 TABLE 628 AUSTRALIA: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2022–2030 (USD MILLION) 493 TABLE 629 AUSTRALIA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2022–2030 (USD MILLION) 494 TABLE 630 AUSTRALIA: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022–2030 (USD MILLION) 494 TABLE 631 AUSTRALIA: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2022–2030 (USD MILLION) 495 TABLE 632 AUSTRALIA: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION) 495 TABLE 633 AUSTRALIA: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2022–2030 (USD MILLION) 496 TABLE 634 AUSTRALIA: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION) 496 TABLE 635 AUSTRALIA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2022–2030 (USD MILLION) 497 TABLE 636 SINGAPORE: KEY MACROECONOMIC INDICATORS 497 TABLE 637 SINGAPORE: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2030 (USD MILLION) 498 TABLE 638 SINGAPORE: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION) 498 TABLE 639 SINGAPORE: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2022–2030 (USD MILLION) 499 TABLE 640 SINGAPORE: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2022–2030 (USD MILLION) 499 TABLE 641 SINGAPORE: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022–2030 (USD MILLION) 500 TABLE 642 SINGAPORE: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2022–2030 (USD MILLION) 500 TABLE 643 SINGAPORE: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION) 501 TABLE 644 SINGAPORE: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2022–2030 (USD MILLION) 501 TABLE 645 SINGAPORE: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION) 502 TABLE 646 SINGAPORE: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2022–2030 (USD MILLION) 502 TABLE 647 REST OF ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2030 (USD MILLION) 503 TABLE 648 REST OF ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION) 503 TABLE 649 REST OF ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2022–2030 (USD MILLION) 504 TABLE 650 REST OF ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2022–2030 (USD MILLION) 504 TABLE 651 REST OF ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022–2030 (USD MILLION) 505 TABLE 652 REST OF ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2022–2030 (USD MILLION) 505 TABLE 653 REST OF ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION) 506 TABLE 654 REST OF ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2022–2030 (USD MILLION) 506 TABLE 655 REST OF ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION) 507 TABLE 656 REST OF ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2022–2030 (USD MILLION) 507 TABLE 657 LATIN AMERICA: KEY MACROECONOMIC INDICATORS 508 TABLE 658 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 509 TABLE 659 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2030 (USD MILLION) 509 TABLE 660 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION) 510 TABLE 661 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2022–2030 (USD MILLION) 510 TABLE 662 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2022–2030 (USD MILLION) 511 TABLE 663 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022–2030 (USD MILLION) 511 TABLE 664 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2022–2030 (USD MILLION) 512 TABLE 665 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION) 512 TABLE 666 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2022–2030 (USD MILLION) 513 TABLE 667 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION) 514 TABLE 668 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2022–2030 (USD MILLION) 514 TABLE 669 BRAZIL: KEY MACROECONOMIC INDICATORS 515 TABLE 670 BRAZIL: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2030 (USD MILLION) 516 TABLE 671 BRAZIL: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION) 516 TABLE 672 BRAZIL: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2022–2030 (USD MILLION) 517 TABLE 673 BRAZIL: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2022–2030 (USD MILLION) 517 TABLE 674 BRAZIL: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022–2030 (USD MILLION) 518 TABLE 675 BRAZIL: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2022–2030 (USD MILLION) 518 TABLE 676 BRAZIL: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION) 519 TABLE 677 BRAZIL: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2022–2030 (USD MILLION) 519 TABLE 678 BRAZIL: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION) 520 TABLE 679 BRAZIL: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2022–2030 (USD MILLION) 520 TABLE 680 MEXICO: KEY MACROECONOMIC INDICATORS 521 TABLE 681 MEXICO: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2030 (USD MILLION) 522 TABLE 682 MEXICO: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION) 522 TABLE 683 MEXICO: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2022–2030 (USD MILLION) 523 TABLE 684 MEXICO: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2022–2030 (USD MILLION) 523 TABLE 685 MEXICO: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022–2030 (USD MILLION) 524 TABLE 686 MEXICO: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2022–2030 (USD MILLION) 524 TABLE 687 MEXICO: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION) 525 TABLE 688 MEXICO: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2022–2030 (USD MILLION) 525 TABLE 689 MEXICO: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION) 526 TABLE 690 MEXICO: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2022–2030 (USD MILLION) 526 TABLE 691 REST OF LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2030 (USD MILLION) 527 TABLE 692 REST OF LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION) 528 TABLE 693 REST OF LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2022–2030 (USD MILLION) 528 TABLE 694 REST OF LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2022–2030 (USD MILLION) 529 TABLE 695 REST OF LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022–2030 (USD MILLION) 529 TABLE 696 REST OF LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2022–2030 (USD MILLION) 530 TABLE 697 REST OF LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION) 530 TABLE 698 REST OF LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2022–2030 (USD MILLION) 531 TABLE 699 REST OF LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION) 532 TABLE 700 REST OF LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2022–2030 (USD MILLION) 532 TABLE 701 MIDDLE EAST & AFRICA: KEY MACROECONOMIC INDICATORS 533 TABLE 702 MIDDLE EAST & AFRICA: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2030 (USD MILLION) 534 TABLE 703 MIDDLE EAST & AFRICA: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION) 534 TABLE 704 MIDDLE EAST & AFRICA: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2022–2030 (USD MILLION) 535 TABLE 705 MIDDLE EAST & AFRICA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2022–2030 (USD MILLION) 535 TABLE 706 MIDDLE EAST & AFRICA: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022–2030 (USD MILLION) 536 TABLE 707 MIDDLE EAST & AFRICA: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2022–2030 (USD MILLION) 536 TABLE 708 MIDDLE EAST & AFRICA: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION) 537 TABLE 709 MIDDLE EAST & AFRICA: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2022–2030 (USD MILLION) 537 TABLE 710 MIDDLE EAST & AFRICA: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION) 538 TABLE 711 MIDDLE EAST & AFRICA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2022–2030 (USD MILLION) 538 TABLE 712 GCC COUNTRIES: KEY MACROECONOMIC INDICATORS 539 TABLE 713 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 539 TABLE 714 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2030 (USD MILLION) 540 TABLE 715 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION) 540 TABLE 716 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2022–2030 (USD MILLION) 541 TABLE 717 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2022–2030 (USD MILLION) 541 TABLE 718 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022–2030 (USD MILLION) 542 TABLE 719 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2022–2030 (USD MILLION) 542 TABLE 720 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION) 543 TABLE 721 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2022–2030 (USD MILLION) 543 TABLE 722 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION) 544 TABLE 723 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2022–2030 (USD MILLION) 544 TABLE 724 SAUDI ARABIA: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2030 (USD MILLION) 545 TABLE 725 SAUDI ARABIA: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION) 545 TABLE 726 SAUDI ARABIA: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2022–2030 (USD MILLION) 546 TABLE 727 SAUDI ARABIA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2022–2030 (USD MILLION) 546 TABLE 728 SAUDI ARABIA: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022–2030 (USD MILLION) 547 TABLE 729 SAUDI ARABIA: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2022–2030 (USD MILLION) 547 TABLE 730 SAUDI ARABIA: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION) 548 TABLE 731 SAUDI ARABIA: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2022–2030 (USD MILLION) 548 TABLE 732 SAUDI ARABIA: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION) 549 TABLE 733 SAUDI ARABIA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2022–2030 (USD MILLION) 549 TABLE 734 UAE: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2030 (USD MILLION) 550 TABLE 735 UAE: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION) 551 TABLE 736 UAE: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2022–2030 (USD MILLION) 552 TABLE 737 UAE: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2022–2030 (USD MILLION) 552 TABLE 738 UAE: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022–2030 (USD MILLION) 553 TABLE 739 UAE: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2022–2030 (USD MILLION) 553 TABLE 740 UAE: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION) 554 TABLE 741 UAE: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2022–2030 (USD MILLION) 554 TABLE 742 UAE: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION) 555 TABLE 743 UAE: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2022–2030 (USD MILLION) 555 TABLE 744 OTHER GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2030 (USD MILLION) 556 TABLE 745 OTHER GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION) 556 TABLE 746 OTHER GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2022–2030 (USD MILLION) 557 TABLE 747 OTHER GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2022–2030 (USD MILLION) 557 TABLE 748 OTHER GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022–2030 (USD MILLION) 558 TABLE 749 OTHER GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2022–2030 (USD MILLION) 558 TABLE 750 OTHER GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION) 559 TABLE 751 OTHER GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2022–2030 (USD MILLION) 559 TABLE 752 OTHER GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION) 560 TABLE 753 OTHER GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2022–2030 (USD MILLION) 560 TABLE 754 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS, JANUARY 2022–APRIL 2025 562 TABLE 755 IN VITRO DIAGNOSTICS MARKET: DEGREE OF COMPETITION 564 TABLE 756 IN VITRO DIAGNOSTICS MARKET: REGION FOOTPRINT 571 TABLE 757 IN VITRO DIAGNOSTICS MARKET: PRODUCT & SERVICE FOOTPRINT 572 TABLE 758 IN VITRO DIAGNOSTICS MARKET: TECHNOLOGY FOOTPRINT 573 TABLE 759 IN VITRO DIAGNOSTICS MARKET: END-USER FOOTPRINT 574 TABLE 760 IN VITRO DIAGNOSTICS MARKET: DETAILED LIST OF KEY STARTUPS/SMES 577 TABLE 761 IN VITRO DIAGNOSTICS MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SMES 578 TABLE 762 IN VITRO DIAGNOSTICS MARKET: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–APRIL 2025 579 TABLE 763 IN VITRO DIAGNOSTICS MARKET: DEALS, JANUARY 2022–APRIL 2025 580 TABLE 764 IN VITRO DIAGNOSTICS MARKET: EXPANSIONS, JANUARY 2022–APRIL 2025 581 TABLE 765 IN VITRO DIAGNOSTICS MARKET: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–MARCH 2025 583 TABLE 766 IN VITRO DIAGNOSTICS MARKET: DEALS, JANUARY 2022–MARCH 2025 583 TABLE 767 AI-DRIVEN PRODUCTS & SERVICES PROVIDED BY KEY PLAYERS 584 TABLE 768 DANAHER: COMPANY OVERVIEW 585 TABLE 769 DANAHER: PRODUCTS/SERVICES OFFERED 587 TABLE 770 DANAHER: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–MARCH 2025 590 TABLE 771 DANAHER: DEALS, JANUARY 2022–MARCH 2025 591 TABLE 772 DANAHER: EXPANSIONS, JANUARY 2022–MARCH 2024 592 TABLE 773 F. HOFFMANN-LA ROCHE LTD: COMPANY OVERVIEW 594 TABLE 774 F. HOFFMANN-LA ROCHE LTD: CURRENCY CONVERSION, 2022–2024 595 TABLE 775 F. HOFFMANN-LA ROCHE LTD: PRODUCTS/SERVICES OFFERED 596 TABLE 776 F. HOFFMANN-LA ROCHE LTD: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–MARCH 2025 599 TABLE 777 F. HOFFMANN-LA ROCHE LTD: DEALS, JANUARY 2022–MARCH 2025 601 TABLE 778 F. HOFFMANN-LA ROCHE LTD: EXPANSIONS, JANUARY 2022–MARCH 2024 602 TABLE 779 ABBOTT: COMPANY OVERVIEW 603 TABLE 780 ABBOTT: PRODUCTS/SERVICES OFFERED 604 TABLE 781 ABBOTT: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–MARCH 2025 607 TABLE 782 ABBOTT: DEALS, JANUARY 2022–MARCH 2025 608 TABLE 783 ABBOTT: EXPANSIONS, JANUARY 2022–MARCH 2025 609 TABLE 784 SIEMENS HEALTHINEERS AG: COMPANY OVERVIEW 610 TABLE 785 SIEMENS HEALTHINEERS AG: CURRENCY CONVERSION, 2022–2024 611 TABLE 786 SIEMENS HEALTHINEERS AG: PRODUCTS/SERVICES OFFERED 612 TABLE 787 SIEMENS HEALTHINEERS AG: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–MARCH 2025 614 TABLE 788 SIEMENS HEALTHINEERS AG: DEALS, JANUARY 2022–MARCH 2025 614 TABLE 789 SIEMENS HEALTHINEERS AG: EXPANSIONS, JANUARY 2022–MARCH 2025 616 TABLE 790 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW 617 TABLE 791 THERMO FISHER SCIENTIFIC INC.: PRODUCTS/SERVICES OFFERED 618 TABLE 792 THERMO FISHER SCIENTIFIC INC.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–MARCH 2025 621 TABLE 793 THERMO FISHER SCIENTIFIC INC.: DEALS, JANUARY 2022–MARCH 2025 622 TABLE 794 THERMO FISHER SCIENTIFIC INC.: EXPANSIONS, JANUARY 2022–MARCH 2025 624 TABLE 795 ILLUMINA, INC.: COMPANY OVERVIEW 626 TABLE 796 ILLUMINA, INC.: PRODUCTS OFFERED 628 TABLE 797 ILLUMINA, INC.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–MARCH 2025 629 TABLE 798 ILLUMINA, INC.: DEALS, JANUARY 2022–MARCH 2025 630 TABLE 799 ILLUMINA, INC.: EXPANSIONS, JANUARY 2022–MARCH 2025 631 TABLE 800 ILLUMINA, INC.: OTHER DEVELOPMENTS, JANUARY 2022–MARCH 2025 632 TABLE 801 HOLOGIC, INC.: COMPANY OVERVIEW 633 TABLE 802 HOLOGIC, INC.: PRODUCTS/SERVICES OFFERED 634 TABLE 803 HOLOGIC, INC.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–MARCH 2025 635 TABLE 804 HOLOGIC, INC.: DEALS, JANUARY 2022–MARCH 2025 636 TABLE 805 HOLOGIC, INC.: EXPANSIONS, JANUARY 2022–MARCH 2025 637 TABLE 806 BIO-RAD LABORATORIES, INC.: COMPANY OVERVIEW 638 TABLE 807 BIO-RAD LABORATORIES, INC.: PRODUCTS/SERVICES OFFERED 640 TABLE 808 BIO-RAD LABORATORIES, INC.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–MARCH 2025 642 TABLE 809 BIO-RAD LABORATORIES, INC.: DEALS, JANUARY 2022–MARCH 2025 643 TABLE 810 BIOMÉRIEUX: COMPANY OVERVIEW 644 TABLE 811 BIOMÉRIEUX: CURRENCY CONVERSION, 2022–2024 645 TABLE 812 BIOMÉRIEUX: PRODUCTS/SERVICES OFFERED 646 TABLE 813 BIOMÉRIEUX: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–MARCH 2025 648 TABLE 814 BIOMÉRIEUX: DEALS, JANUARY 2022–MARCH 2025 649 TABLE 815 BIOMÉRIEUX: EXPANSIONS, JANUARY 2022–MARCH 2025 650 TABLE 816 SYSMEX CORPORATION: COMPANY OVERVIEW 651 TABLE 817 SYSMEX CORPORATION: CURRENCY CONVERSION, 2022–2024 652 TABLE 818 SYSMEX CORPORATION: PRODUCTS/SERVICES OFFERED 653 TABLE 819 SYSMEX CORPORATION: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–MARCH 2025 654 TABLE 820 SYSMEX CORPORATION: DEALS, JANUARY 2022–MARCH 2025 655 TABLE 821 SYSMEX CORPORATION: EXPANSIONS, JANUARY 2022–MARCH 2025 656 TABLE 822 REVVITY: COMPANY OVERVIEW 657 TABLE 823 REVVITY: PRODUCTS/SERVICES OFFERED 659 TABLE 824 REVVITY: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–MARCH 2025 660 TABLE 825 REVVITY: DEALS, JANUARY 2022–MARCH 2025 661 TABLE 826 REVVITY: OTHER DEVELOPMENTS, JANUARY 2022–MARCH 2025 661 TABLE 827 BECTON, DICKINSON AND COMPANY: COMPANY OVERVIEW 662 TABLE 828 BECTON, DICKINSON AND COMPANY: PRODUCTS/SERVICES OFFERED 663 TABLE 829 BECTON, DICKINSON AND COMPANY: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–MARCH 2025 666 TABLE 830 BECTON, DICKINSON AND COMPANY: DEALS, JANUARY 2022–MARCH 2025 666 TABLE 831 BECTON, DICKINSON AND COMPANY: EXPANSIONS, JANUARY 2022–MARCH 2025 667 TABLE 832 AGILENT TECHNOLOGIES, INC.: COMPANY OVERVIEW 668 TABLE 833 AGILENT TECHNOLOGIES, INC: PRODUCTS/SERVICES OFFERED 670 TABLE 834 AGILENT TECHNOLOGIES, INC: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–MARCH 2025 672 TABLE 835 AGILENT TECHNOLOGIES, INC: DEALS, JANUARY 2022–MARCH 2025 673 TABLE 836 AGILENT TECHNOLOGIES, INC: OTHER DEVELOPMENTS, JANUARY 2022–MARCH 2025 674 TABLE 837 QIAGEN: COMPANY OVERVIEW 675 TABLE 838 QIAGEN: PRODUCTS/SERVICES OFFERED 677 TABLE 839 QIAGEN: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–MARCH 2025 680 TABLE 840 QIAGEN: DEALS, JANUARY 2022–MARCH 2025 682 TABLE 841 DIASORIN S.P.A.: COMPANY OVERVIEW 683 TABLE 842 DIASORIN S.P.A.: CURRENCY CONVERSION, 2021-2023 684 TABLE 843 DIASORIN S.P.A.: PRODUCTS/SERVICES OFFERED 685 TABLE 844 DIASORIN S.P.A.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–MARCH 2025 687 TABLE 845 DIASORIN S.P.A.: DEALS, JANUARY 2022–MARCH 2025 688 TABLE 846 GRIFOLS, S.A.: COMPANY OVERVIEW 689 TABLE 847 GRIFOLS, S.A.: CURRENCY CONVERSION, 2022–2024 690 TABLE 848 GRIFOLS, S.A.: PRODUCTS/SERVICES OFFERED 691 TABLE 849 GRIFOLS, S.A.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–MARCH 2025 691 TABLE 850 GRIFOLS, S.A.: DEALS, JANUARY 2022–MARCH 2025 692 TABLE 851 WERFEN: COMPANY OVERVIEW 693 TABLE 852 WERFEN: PRODUCTS/SERVICES OFFERED 695 TABLE 853 WERFEN: DEALS, JANUARY 2022–MARCH 2025 696 TABLE 854 WERFEN: EXPANSIONS, JANUARY 2022–MARCH 2025 697 TABLE 855 QUIDELORTHO CORPORATION: COMPANY OVERVIEW 698 TABLE 856 QUIDELORTHO CORPORATION: PRODUCTS/SERVICES OFFERED 700 TABLE 857 QUIDELORTHO CORPORATION: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–MARCH 2025 702 TABLE 858 QUIDELORTHO CORPORATION: DEALS, JANUARY 2022–MARCH 2025 703 TABLE 859 QUIDELORTHO CORPORATION: EXPANSIONS, JANUARY 2022–MARCH 2024 703 TABLE 860 DEVYSER: COMPANY OVERVIEW 704 TABLE 861 BIOSYNEX SA: COMPANY OVERVIEW 705 TABLE 862 SURMODICS, INC.: COMPANY OVERVIEW 706 TABLE 863 MENARINI SILICON BIOSYSTEMS: COMPANY OVERVIEW 707 TABLE 864 SPEEDX PTY. LTD.: COMPANY OVERVIEW 708 TABLE 865 GENSPEED BIOTECH GMBH: COMPANY OVERVIEW 709 TABLE 866 MERCK KGAA: COMPANY OVERVIEW 710 TABLE 867 CARIS LIFE SCIENCES: COMPANY OVERVIEW 712 TABLE 868 ARKRAY, INC.: COMPANY OVERVIEW 713 TABLE 869 ACCELERATE DIAGNOSTICS, INC.: COMPANY OVERVIEW 714 TABLE 870 CELLABS: COMPANY OVERVIEW 715 TABLE 871 J. MITRA & CO. PVT. LTD.: COMPANY OVERVIEW 716 TABLE 872 EPITOPE DIAGNOSTICS, INC.: COMPANY OVERVIEW 717 TABLE 873 BOSTER BIOLOGICAL TECHNOLOGY: COMPANY OVERVIEW 718 TABLE 874 ENZO BIOCHEM INC.: COMPANY OVERVIEW 719 TABLE 875 GENETIC SIGNATURES: COMPANY OVERVIEW 720 TABLE 876 SAVYON DIAGNOSTICS: COMPANY OVERVIEW 721 TABLE 877 TRIVITRON HEALTHCARE: COMPANY OVERVIEW 722 TABLE 878 MDXHEALTH: COMPANY OVERVIEW 723 TABLE 879 CREATIVE DIAGNOSTICS: COMPANY OVERVIEW 724 TABLE 880 INBIOS INTERNATIONAL, INC.: COMPANY OVERVIEW 725 TABLE 881 MACCURA BIOTECHNOLOGY CO., LTD.: COMPANY OVERVIEW 726 TABLE 882 LUYE LIFE SCIENCES GROUP: COMPANY OVERVIEW 727 FIGURE 1 IN VITRO DIAGNOSTICS MARKET SEGMENTATION AND REGIONAL SCOPE 58 FIGURE 2 RESEARCH DESIGN 62 FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS 68 FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 68 FIGURE 5 GLOBAL IN VITRO DIAGNOSTICS MARKET: REVENUE SHARE ANALYSIS 69 FIGURE 6 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 70 FIGURE 7 TOP-DOWN APPROACH 71 FIGURE 8 DATA TRIANGULATION METHODOLOGY 72 FIGURE 9 IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2025 VS. 2030 (USD MILLION) 75 FIGURE 10 IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2025 VS. 2030 (USD MILLION) 76 FIGURE 11 IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2025 VS. 2030 (USD MILLION) 77 FIGURE 12 IN VITRO DIAGNOSTICS MARKET, BY SITE OF TESTING, 2025 VS. 2030 (USD MILLION) 77 FIGURE 13 IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2025 VS. 2030 (USD MILLION) 78 FIGURE 14 IN VITRO DIAGNOSTICS MARKET, BY END USER, 2025 VS. 2030 (USD MILLION) 79 FIGURE 15 GEOGRAPHIC SNAPSHOT OF IN VITRO DIAGNOSTICS MARKET 80 FIGURE 16 GROWING PREVALENCE OF INFECTIOUS DISEASES AND RISING EMPHASIS ON NEED FOR EARLY DIAGNOSIS TO DRIVE MARKET 82 FIGURE 17 REAGENTS & KITS SEGMENT AND US LED NORTH AMERICAN IN VITRO DIAGNOSTICS MARKET IN 2024 83 FIGURE 18 CHINA TO REGISTER HIGHEST CAGR DURING FORECAST PERIOD 84 FIGURE 19 ASIA PACIFIC TO WITNESS HIGHEST GROWTH DURING FORECAST PERIOD 84 FIGURE 20 EMERGING ECONOMIES TO REGISTER HIGHER GROWTH DURING FORECAST PERIOD 85 FIGURE 21 IN VITRO DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 86 FIGURE 22 IN VITRO DIAGNOSTIC REGULATION: CRITICAL AREAS OF IMPACT 91 FIGURE 23 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS 98 FIGURE 24 IN VITRO DIAGNOSTICS MARKET: VALUE CHAIN ANALYSIS 103 FIGURE 25 IN VITRO DIAGNOSTICS MARKET: SUPPLY CHAIN ANALYSIS 104 FIGURE 26 IN VITRO DIAGNOSTICS MARKET: ECOSYSTEM MAPPING 105 FIGURE 27 IN VITRO DIAGNOSTICS MARKET: INVESTMENT AND FUNDING SCENARIO, 2020−2023 106 FIGURE 28 IN VITRO DIAGNOSTICS MARKET: PATENT ANALYSIS, 2014–2024 109 FIGURE 29 US: REGULATORY PROCESS FOR IVD DEVICES 119 FIGURE 30 CANADA: REGULATORY PROCESS FOR IVD DEVICES IN CANADA 120 FIGURE 31 EUROPE: IN VITRO DIAGNOSTIC REGULATION (IVDR) TIMELINE 121 FIGURE 32 REGULATORY PROCESS FOR IVD DEVICES IN JAPAN 122 FIGURE 33 INDIA: REGULATORY PROCESS FOR IVD DEVICES 124 FIGURE 34 MEXICO: REGULATORY PROCESS FOR IVD DEVICES 127 FIGURE 35 IN VITRO DIAGNOSTICS MARKET: PORTER’S FIVE FORCES ANALYSIS 129 FIGURE 36 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF IVD PRODUCTS, BY PRODUCT & SERVICE 131 FIGURE 37 KEY BUYING CRITERIA, BY PRODUCT & SERVICE 132 FIGURE 38 AI USE CASES 139 FIGURE 39 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET SNAPSHOT 385 FIGURE 40 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET SNAPSHOT 461 FIGURE 41 IN VITRO DIAGNOSTICS MARKET: REVENUE ANALYSIS OF KEY PLAYERS, 2022–2024 (USD BILLION) 563 FIGURE 42 IN VITRO DIAGNOSTICS MARKET SHARE ANALYSIS, 2024 564 FIGURE 43 RANKING OF KEY PLAYERS, 2024 566 FIGURE 44 EV/EBITDA OF KEY VENDORS, 2025 566 FIGURE 45 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS, 2025 567 FIGURE 46 IN VITRO DIAGNOSTICS MARKET: BRAND/PRODUCT COMPARISON 567 FIGURE 47 IN VITRO DIAGNOSTICS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024 569 FIGURE 48 IN VITRO DIAGNOSTICS MARKET: COMPANY FOOTPRINT 570 FIGURE 49 IN VITRO DIAGNOSTICS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024 576 FIGURE 50 DANAHER: COMPANY SNAPSHOT (2024) 586 FIGURE 51 F. HOFFMANN-LA ROCHE LTD: COMPANY SNAPSHOT (2024) 595 FIGURE 52 ABBOTT: COMPANY SNAPSHOT (2024) 604 FIGURE 53 SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT (2024) 611 FIGURE 54 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2024) 618 FIGURE 55 ILLUMINA, INC.: COMPANY SNAPSHOT (2024) 627 FIGURE 56 HOLOGIC, INC.: COMPANY SNAPSHOT (2024) 634 FIGURE 57 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2024) 639 FIGURE 58 BIOMÉRIEUX: COMPANY SNAPSHOT (2024) 645 FIGURE 59 SYSMEX CORPORATION: COMPANY SNAPSHOT (2024) 652 FIGURE 60 REVVITY: COMPANY SNAPSHOT (2024) 658 FIGURE 61 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2024) 663 FIGURE 62 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2024) 669 FIGURE 63 QIAGEN: COMPANY SNAPSHOT (2024) 676 FIGURE 64 DIASORIN S.P.A: COMPANY SNAPSHOT (2023) 684 FIGURE 65 GRIFOLS, S.A.: COMPANY SNAPSHOT (2024) 690 FIGURE 66 WERFEN: COMPANY SNAPSHOT (2024) 694 FIGURE 67 QUIDELORTHO CORPORATION: COMPANY SNAPSHOT (2024) 699

同分類最新報告（醫療器材）

查看醫療器材全部報告 →

量子訊息有限公司為 MarketsandMarkets 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們